<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006611</article-id><article-id pub-id-type="pmc">PMC11860060</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020244</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00244</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Recent Advances in Glutathione Depletion-Enhanced Porphyrin-Based nMOFs for Photodynamic Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gong</surname><given-names>Bin</given-names></name><xref rid="af1-pharmaceutics-17-00244" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Qiuyun</given-names></name><xref rid="af2-pharmaceutics-17-00244" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jiayi</given-names></name><xref rid="af2-pharmaceutics-17-00244" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Qu</surname><given-names>Yijie</given-names></name><xref rid="af2-pharmaceutics-17-00244" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Xuanxuan</given-names></name><xref rid="af2-pharmaceutics-17-00244" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3296-7078</contrib-id><name><surname>Wang</surname><given-names>Weiqi</given-names></name><xref rid="af2-pharmaceutics-17-00244" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-17-00244" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8045-279X</contrib-id><name><surname>Zheng</surname><given-names>Xiaohua</given-names></name><xref rid="af2-pharmaceutics-17-00244" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-17-00244" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Nowakowska</surname><given-names>Maria</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Savu</surname><given-names>Diana</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Popescu</surname><given-names>Roxana Cristina</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00244"><label>1</label>The People&#x02019;s Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang 212300, China</aff><aff id="af2-pharmaceutics-17-00244"><label>2</label>School of Pharmacy, Nantong University, Nantong 226001, China</aff><author-notes><corresp id="c1-pharmaceutics-17-00244"><label>*</label>Correspondence: <email>wwq1990@ntu.edu.cn</email> (W.W.); <email>xiaohuaz@ntu.edu.cn</email> (X.Z.)</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>244</elocation-id><history><date date-type="received"><day>28</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>28</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Photodynamic therapy has established itself as a clinical treatment for certain superficial cancers by converting oxygen into cytotoxic singlet oxygen to eradicate cancer cells. Porphyrin-based nanoscale metal&#x02013;organic frameworks have emerged as promising photosensitive platforms due to their ability to prevent the hydrophobic aggregation quenching of porphyrin molecules and enhance accumulation at the tumor site, thereby becoming a focal point in photodynamic materials research. However, the elevated levels of glutathione and other reductive substances within cancer cells can alleviate the oxidative stress induced by singlet oxygen from the photodynamic therapy process, thus protecting intracellular biomolecular structures from damage. Consequently, it is crucial to design functionalized nanoplatforms that integrate glutathione depletion with porphyrin-based metal&#x02013;organic frameworks to significantly boost photodynamic therapy efficacy. Moreover, the excess glutathione within cells can disrupt the structure of porphyrin-based metal&#x02013;organic frameworks, which not only increases the capacity of porphyrin molecules to generate singlet oxygen upon light exposure but also aids in the recovery of their fluorescence imaging capabilities. Additionally, this specificity minimizes the photosensitizing harm of porphyrin-based metal&#x02013;organic frameworks to other normal tissues. This review compiles recent advancements in developing porphyrin-based metal&#x02013;organic frameworks for enhanced phototherapy through glutathione depletion. It aims to promote the further application of porphyrin-based metal&#x02013;organic frameworks in phototherapy and provide valuable insights for preclinical applications. By highlighting strategies that improve therapeutic outcomes while maintaining safety profiles, this summary seeks to advance the development of more effective and targeted cancer treatments.</p></abstract><kwd-group><kwd>porphyrin</kwd><kwd>metal&#x02013;organic frameworks</kwd><kwd>photodynamic therapy</kwd><kwd>singlet oxygen</kwd><kwd>glutathione depletion</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>52103169</award-id></award-group><funding-statement>This work was supported by the National Natural Science Foundation of China (52103169).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00244"><title>1. Introduction</title><p>Malignant tumors pose significant therapeutic challenges due to their heterogeneity and specific microenvironment [<xref rid="B1-pharmaceutics-17-00244" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00244" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00244" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-17-00244" ref-type="bibr">4</xref>]. Photodynamic therapy (PDT) emerges as an efficient treatment modality with several unique advantages: it is operationally simple, cost-effective, noninvasive, and does not induce drug resistance [<xref rid="B5-pharmaceutics-17-00244" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-00244" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00244" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00244" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00244" ref-type="bibr">9</xref>]. These attributes make PDT, which kills cancer cells through the generation of highly reactive oxygen species (ROS), an exceptionally promising and widely researched antitumor approach [<xref rid="B10-pharmaceutics-17-00244" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-00244" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-17-00244" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-00244" ref-type="bibr">13</xref>]. The process of PDT involves a light-activated photosensitizer facilitating energy transfer or electron transfer to produce oxidative ROS [<xref rid="B14-pharmaceutics-17-00244" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00244" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00244" ref-type="bibr">16</xref>]. Among various photosensitizers, porphyrins and their derivatives, characterized by four pyrrole rings conjugated with methine bridges, stand out for their excellent biocompatibility, photostability, and singlet-oxygen-generation capability [<xref rid="B17-pharmaceutics-17-00244" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00244" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-00244" ref-type="bibr">19</xref>]. Despite these advantages, porphyrin molecules, especially those with tetraphenyl structures, exhibit strong hydrophobicity leading to aggregation in aqueous solutions [<xref rid="B20-pharmaceutics-17-00244" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-17-00244" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-17-00244" ref-type="bibr">22</xref>]. Thus, developing carriers that enhance the dispersion stability and accumulation concentration of porphyrin photosensitizers at the tumor site is crucial for improving PDT efficacy [<xref rid="B23-pharmaceutics-17-00244" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-17-00244" ref-type="bibr">24</xref>].</p><p>Among the diverse carrier materials, researchers have found that designing nanoscale metal&#x02013;organic frameworks (nMOFs) by coordinating porphyrins with metals significantly enhances the physiological solution dispersibility, singlet oxygen production efficiency, and accumulation capacity of porphyrin photosensitizers [<xref rid="B25-pharmaceutics-17-00244" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00244" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00244" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00244" ref-type="bibr">28</xref>]. Numerous materials are used as carriers for porphyrin in phototherapy, but nMOF materials exhibit distinct advantages. Polymers can be employed to achieve the loading of porphyrin molecules; however, this method relies on the interaction between hydrophobic blocks of amphiphilic polymers and hydrophobic porphyrin molecules, which does not entirely prevent the aggregation of porphyrin molecules. Liposomes can also be utilized for loading porphyrin molecules, yet they often fail to achieve optimal loading capacity and cannot avoid the aggregation of porphyrin molecules. Inorganic materials such as silica spheres can also load porphyrin molecules, but the aggregation of porphyrin within these carriers commonly leads to quenching, affecting the production of <sup>1</sup>O<sub>2</sub> by porphyrin molecules. In contrast, incorporating porphyrin into framework materials to prepare nMOFs offers several advantages. Firstly, the periodic and ordered structure of nMOFs can completely prevent the aggregation of hydrophobic porphyrin molecules. Secondly, the porous nature of porphyrin-based nMOFs facilitates the diffusion of O<sub>2</sub> molecules into the material and the subsequent diffusion of produced <sup>1</sup>O<sub>2</sub> outwards. Additionally, the porous structure of porphyrin-based nMOFs supports the loading of other drug molecules, enabling combined therapeutic effects. This makes porphyrin-based nMOFs one of the most promising candidates for clinical applications requiring photoactive materials. Lastly, the large specific surface area of porphyrin-based nMOFs facilitates further modifications with polymers to enhance their targeting capability [<xref rid="B29-pharmaceutics-17-00244" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00244" ref-type="bibr">30</xref>]. Therefore, phototherapy materials based on porphyrin-based nMOFs possess significant research value. However, high intracellular glutathione (GSH) concentrations in cancer cells, aimed at maintaining redox homeostasis, can greatly limit the effectiveness of ROS-generating therapies such as PDT, sonodynamic therapy (SDT), chemodynamic therapy (CDT), ferroptosis therapy, and radiotherapy [<xref rid="B31-pharmaceutics-17-00244" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00244" ref-type="bibr">32</xref>]. Reducing intracellular GSH levels to prevent ROS scavenging is therefore an effective strategy to enhance PDT efficacy [<xref rid="B33-pharmaceutics-17-00244" ref-type="bibr">33</xref>].</p><p>Intracellular glutathione peroxidase can lower GSH levels, but the large molecular structure of glutathione peroxidase necessitates complex delivery system designs [<xref rid="B31-pharmaceutics-17-00244" ref-type="bibr">31</xref>]. The inherent instability of enzymes may impose limitations on their prolonged application as therapeutic agents for modulating GSH levels. Interestingly, GSH, as a thiol-containing reductant, can reduce various metal ions including Cu<sup>2+</sup>, Mn<sup>3+</sup>, and Fe<sup>3+</sup> [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00244" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00244" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-00244" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-17-00244" ref-type="bibr">39</xref>]. Notably, these metal ions can coordinate with meso-tetra(4-carboxyphenyl)porphyrin (TCPP) molecules to form MOF materials [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>]. This enables a straightforward combination of GSH depletion and porphyrin-mediated PDT without the need for a complex design, presenting a promising method for treating malignant tumors [<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>]. Moreover, under the weakly acidic conditions within cancer cells, GSH can disrupt the structure of Cu<sup>2+</sup>-, Mn<sup>3+</sup>-, and Fe<sup>3+</sup>-based nMOFs, releasing porphyrin photosensitizers [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>]. This further promotes <sup>1</sup>O<sub>2</sub> production and fluorescence recovery, enabling fluorescence imaging-guided therapy [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>]. Importantly, this GSH-activated enhanced PDT effect can also minimize damage to normal cells by photoactive nMOFs.</p><p>In 2021, Yang et al. systematically and comprehensively discussed the progress of engineered nanomedicines in enhancing cancer therapies through GSH depletion [<xref rid="B31-pharmaceutics-17-00244" ref-type="bibr">31</xref>]. Wu et al. summarized the synergistic therapeutic effects of GSH-scavenging nanomedicines in conjunction with PDT, CDT, radiotherapy, and chemotherapy [<xref rid="B32-pharmaceutics-17-00244" ref-type="bibr">32</xref>]. Niu et al. further elucidated how the GSH depletion mechanism enhances treatments based on ROS, promotes ferroptosis, and improves chemotherapy efficacy [<xref rid="B33-pharmaceutics-17-00244" ref-type="bibr">33</xref>]. Subsequently, Wang et al. specifically highlighted the enhancement effects of GSH scavenging on SDT [<xref rid="B40-pharmaceutics-17-00244" ref-type="bibr">40</xref>]. This review concentrates on an in-depth summary of recent research over the past few years concerning the enhancement of PDT efficacy using porphyrin-based nMOF materials through GSH-scavenging capabilities. It details the molecular mechanisms of various systems designed to reduce GSH, and compares the impact of GSH presence on the <sup>1</sup>O<sub>2</sub> yield from porphyrin-based nMOFs under light exposure. This review systematically outlines the methodologies for integrating redox-active metals within porphyrin-based nMOFs, assessing both the strengths and challenges associated with each approach (<xref rid="pharmaceutics-17-00244-f001" ref-type="fig">Figure 1</xref>). It also elucidates the advantages of employing redox-active metals as formulations for GSH depletion. These metals offer several key benefits: (1) they can directly and effectively deplete GSH via high-valence states [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>]; (2) they can also mimic catalase activity to catalyze the decomposition of the higher concentrations of H<sub>2</sub>O<sub>2</sub> found in cancer cells into O<sub>2</sub>, which not only mitigates hypoxia in cancerous tissues but also facilitates the generation of <sup>1</sup>O<sub>2</sub> [<xref rid="B35-pharmaceutics-17-00244" ref-type="bibr">35</xref>]; (3) upon reduction, they can react with the high concentrations of H<sub>2</sub>O<sub>2</sub> within cancer cells to yield hydroxyl radicals&#x02014;potent oxidants that markedly augment the therapeutic potential of ROS-based treatments (<xref rid="pharmaceutics-17-00244-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>]. Finally, this review evaluates the therapeutic effects and application prospects of these systems on malignant tumors and infected wounds at both cellular and animal levels. The review aims to provide valuable insights for the clinical research of porphyrin-based nMOFs.</p></sec><sec id="sec2-pharmaceutics-17-00244"><title>2. Advantages of Metals as GSH Depleters and Effects of Loading Methods</title><p>Cancer cells have evolved various reductive mechanisms to counteract the effects of ROS on their survival [<xref rid="B41-pharmaceutics-17-00244" ref-type="bibr">41</xref>]. These reductive substances include GSH, vitamin C, vitamin E, thioredoxin reductase, catalase, superoxide dismutase (SOD), and others [<xref rid="B41-pharmaceutics-17-00244" ref-type="bibr">41</xref>]. Among them, GSH&#x02014;a tripeptide composed of glutamic acid (Glu), cysteine (Cys), and glycine (Gly)&#x02014;has been extensively studied due to its unique role within cells (<xref rid="pharmaceutics-17-00244-f002" ref-type="fig">Figure 2</xref>A) [<xref rid="B31-pharmaceutics-17-00244" ref-type="bibr">31</xref>]. GSH is one of the most important antioxidants in cancer cells, capable of neutralizing ROS by forming its oxidized form, glutathione disulfide (GSSG), thereby mitigating the therapeutic impact of ROS-based treatments (<xref rid="pharmaceutics-17-00244-f002" ref-type="fig">Figure 2</xref>A) [<xref rid="B32-pharmaceutics-17-00244" ref-type="bibr">32</xref>]. Reducing intracellular GSH levels not only amplifies the efficacy of ROS-mediated therapies but also diminishes the resistance of some cancer cells to chemotherapeutic agents, presenting a novel approach for treating drug-resistant cancer cells [<xref rid="B32-pharmaceutics-17-00244" ref-type="bibr">32</xref>]. Strategies to decrease GSH concentration in cancer cells are numerous, including the pretreatment of phenethyl isothiocyanate, quercetin, buthionine sulfoximine (BSO), and valproic acid (VPA), among others. These molecules reduce cellular GSH either by directly scavenging GSH or inhibiting its synthesis pathways [<xref rid="B42-pharmaceutics-17-00244" ref-type="bibr">42</xref>]. However, these compounds often require structural modifications to enhance their therapeutic potency. Moreover, they typically only serve to lower GSH levels without providing additional biomedical functionalities.</p><p>Research has shown that certain redox-active metals can not only interact directly with GSH to reduce its concentration but also react with H<sub>2</sub>O<sub>2</sub> to produce O<sub>2</sub>, thus alleviating hypoxic microenvironments that limit PDT [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>]. Additionally, these processes can generate lower-valent metals which then react with intracellular H<sub>2</sub>O<sub>2</sub> to produce highly oxidative hydroxyl radicals, further enhancing ROS-mediated therapeutic effects [<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>]. Another advantage of these metals is their stability and ability to restore their oxidation state through reactions with H<sub>2</sub>O<sub>2</sub>, allowing repeated GSH depletion. Furthermore, some of these metals possess CT or MR imaging capabilities, potentially integrating diagnostics with therapy [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>]. Upon reviewing the literature, it was found that porphyrin-based nMOFs can incorporate metals through different methods. The first method involves coordination with TCPP as linker to form the MOF structure (<xref rid="pharmaceutics-17-00244-f002" ref-type="fig">Figure 2</xref>B). This loading method is relatively simple and allows for a high metal load. The second method involves synthesizing linear porphyrin-based MOFs and subsequently coordinating divalent ions such as Cu<sup>2+</sup> at defect sites of the carboxylate ligands to achieve functional metal loading (<xref rid="pharmaceutics-17-00244-f002" ref-type="fig">Figure 2</xref>C). This method facilitates interaction between the loaded metals and intracellular GSH, although it may result in lower metal loads. The third method entails constructing core&#x02013;shell structures or other composites using porphyrin-based nMOFs combined with metal oxides or upconversion nanoparticles (UCNPs) (<xref rid="pharmaceutics-17-00244-f002" ref-type="fig">Figure 2</xref>D). This approach offers advantages, such as introducing new functionalities from metal oxides or upconversion materials, although the preparation process is more complex and the reaction of metal oxides with intracellular GSH might be hindered if used as the core structure. Overall, porphyrin-based nMOFs provide multiple pathways for achieving effective GSH depletion when combined with metals, enabling the delivery of various metals and their oxides into cells while exerting corresponding nanomedicine functions. Therefore, metal-induced GSH depletion to enhance the PDT efficacy of porphyrin-based nMOFs is not only effective and feasible but also holds significant application potential.</p></sec><sec id="sec3-pharmaceutics-17-00244"><title>3. Synthesis of Porphyrin-Based nMOFs and Their GSH Depletion Mechanisms</title><p>MOFs have garnered extensive attention as biomedicine carrier materials due to their diversity and designability [<xref rid="B43-pharmaceutics-17-00244" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-17-00244" ref-type="bibr">44</xref>]. Numerous studies and developments have focused on designing systems that reduce intracellular GSH levels, thereby enhancing the inhibitory effects of MOF materials on cancer cells [<xref rid="B45-pharmaceutics-17-00244" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-17-00244" ref-type="bibr">46</xref>]. Notably, GSH depletion can significantly augment the anticancer efficacy of porphyrin-based nMOFs (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>). For instance, Cai et al. fabricated an Fe-coordinated porphyrin ligand molecule and coordinated it with Cu<sup>2+</sup> ions to obtain Cu-TCPP(Fe) MOF materials (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>) [<xref rid="B45-pharmaceutics-17-00244" ref-type="bibr">45</xref>]. They then utilized a nucleation method to grow Au NPs with an average diameter of 2.8 nm on the MOF surface and loaded RSL3 (an inhibitor of glutathione peroxidase 4 (GPX4)) molecules via &#x003c0;-&#x003c0; stacking. The authors found that Au NPs exhibit glucose oxidase-like activity, leading to substantial consumption of intracellular glucose and hindering GSH synthesis pathways. Moreover, the presence of Cu<sup>2+</sup> ions can oxidize GSH into its oxidized form, GSSG, effectively depleting cellular reductive substances and enhancing ferroptosis damage (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>). Jiang et al. reported that Cu-TCPP can overcome dependencies on oxygen and external excitation light sources (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>) [<xref rid="B46-pharmaceutics-17-00244" ref-type="bibr">46</xref>]. It selectively kills tumor cells by utilizing excess hydrogen peroxide within cancer cells. In the weakly acidic environment inside cancer cells, TCPP molecules in the Cu-TCPP nanoplatform can be peroxidized by excessive hydrogen peroxide through the Russell mechanism. In the presence of Cu-TCPP and trace amounts of Cu<sup>2+</sup> ions, this leads to the generation of peroxyl radicals (ROO&#x000b7;), which subsequently undergo rearrangement reactions within cells to produce singlet oxygen. The generated Cu<sup>2+</sup> ions lower intracellular GSH concentration, thus preventing these antioxidants from protecting cells against oxidative damage. Ultimately, this system achieves enhanced chemotherapy by depleting GSH, exploiting the microenvironment of hypoxic tumors for effective inhibition (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>). Zhao et al. used disulfide-linked imidazole ligands coordinated with Zn<sup>2+</sup> ions to prepare MOF NPs and loaded them with Chlorin e6 (Ce6) molecules to obtain Ce6@RMOF materials [<xref rid="B47-pharmaceutics-17-00244" ref-type="bibr">47</xref>]. The presence of disulfide bonds enables the oxidation of GSH into GSSG. The depletion of GSH further leads to the inactivation of GPX4, ultimately achieving the combined therapeutic effects of ferroptosis and PDT (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>). Beyond metal ions with variable valence states and disulfide/thiol transformations, azo bonds may also lead to the reduction of intracellular GSH and other reductants [<xref rid="B48-pharmaceutics-17-00244" ref-type="bibr">48</xref>]. For example, Guo et al. developed an MOF using azo-containing imidazole ligands coordinated with Zn<sup>2+</sup> ions as a carrier for the photosensitizer Ce6, forming the MOF@Ce6 nanoplatform [<xref rid="B48-pharmaceutics-17-00244" ref-type="bibr">48</xref>]. Within hypoxic cancer cells, azoreductases degrade the MOF@Ce6, simultaneously depleting nicotinamide adenine dinucleotide phosphate (NADPH). Since NADPH serves as an electron donor for reductive substances including GSH and thioredoxin (Trx), its reduced concentration decreases intracellular GSH and Trx levels, amplifying the PDT effect produced by Ce6-generated ROS (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>). Zhang et al. prepared a nanoscale copper-coordinated polymer (CCP) by coordinating Cu<sup>2+</sup> with Zn protoporphyrin IX [<xref rid="B49-pharmaceutics-17-00244" ref-type="bibr">49</xref>]. Intracellular GSH reacts with Cu<sup>2+</sup> within the CCP framework, generating Cu<sup>+</sup> ions. This process not only lowers intracellular GSH concentrations but also releases Zn protoporphyrin IX, which effectively inhibits the activity of the antioxidant heme oxygenase-1. Furthermore, the generated Cu<sup>+</sup> ions react with intracellular hydrogen peroxide to produce hydroxyl radicals, undergoing a chemodynamic process, ultimately enhancing the CDT anticancer effect by inhibiting intracellular reductive substances (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>). Yang et al. formed the highly chemically stable PCN-224 MOF material by coordinating Zr<sup>4+</sup> with TCPP and achieved Cu<sup>2+</sup> loading through PCN-224&#x02019;s unique structure, obtaining the PCN-224(Cu) nanoplatform [<xref rid="B50-pharmaceutics-17-00244" ref-type="bibr">50</xref>]. Cu<sup>2+</sup> in this nanoplatform reduces intracellular GSH concentrations, while the generated Cu<sup>+</sup> undergoes the Fenton reaction with H<sub>2</sub>O<sub>2</sub> to produce hydroxyl radicals, resulting in an enhanced ROS-mediated suppression of cancer cell proliferation (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>). Lin et al. demonstrated that ZIF-8 has oxygen storage capacity, though weaker than Cu<sup>2+</sup>-based MOFs [<xref rid="B51-pharmaceutics-17-00244" ref-type="bibr">51</xref>]. Therefore, they doped Cu<sup>2+</sup> into the ZIF-8 framework to enhance O<sub>2</sub> storage capability and integrated Ce6 photosensitizer molecules into the nanoplatform. Upon entering cells, the platform releases Cu<sup>2+</sup>, which reduces GSH concentration, and the generated Cu<sup>+</sup> ions react with hydrogen peroxide to produce hydroxyl radicals for CDT. Finally, this nanoplatform realizes synergistic CDT and PDT effects enhanced by Cu<sup>2+</sup>-induced oxygen storage and GSH depletion (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>). Xu et al. prepared Mn-coordinated TCPP molecules (Mn-TCPP) and synthesized Mn-MOF via solvothermal reactions with Zr<sup>4+</sup> ions [<xref rid="B52-pharmaceutics-17-00244" ref-type="bibr">52</xref>]. They discovered that the Mn-MOF nanoplatform reacts with excess H<sub>2</sub>O<sub>2</sub> within cancer cells, producing oxygen through Mn<sup>3+</sup>/Mn<sup>4+</sup> dynamic conversion to improve the hypoxic state. Meanwhile, the metal nodes of the Mn-MOF lower intracellular GSH concentration, realizing enhanced SDT and ferroptosis combined treatment mechanisms (<xref rid="pharmaceutics-17-00244-t001" ref-type="table">Table 1</xref>).</p><p>These systems demonstrate that reducing intracellular GSH in cancer cells is an effective and worthwhile strategy for antitumor proliferation, especially when combined with treatments such as CDT, SDT, ferroptosis, and PDT, all of which rely on ROS to inhibit cancer cell proliferation. The modifiability and multifunctionality of MOFs allow these combined therapies to be seamlessly integrated into a single nanoplatform. This review mainly summarizes the role mechanisms and antitumor principles of research work involving metal ions (Mn<sup>3+</sup>, Mn<sup>4+</sup>, Fe<sup>3+</sup>, and Cu<sup>2+</sup>) that consume intracellular GSH to enhance the PDT-related treatment effects of MOF nanoplatforms based on TCPP molecules (<xref rid="pharmaceutics-17-00244-t002" ref-type="table">Table 2</xref>). Summarizing these research efforts provides new insights into how porphyrin-based nMOFs can exploit the unique tumor microenvironment of cancer cells to achieve enhanced therapeutic effects.</p></sec><sec id="sec4-pharmaceutics-17-00244"><title>4. Mn(III)-TCPP nMOF-Induced GSH Depletion for Enhanced PDT</title><p>Porphyrin photosensitizers exhibit excellent biocompatibility, but their poor water solubility has limited their application in biomedical fields [<xref rid="B53-pharmaceutics-17-00244" ref-type="bibr">53</xref>]. Extensive research indicates that constructing porous MOFs through the coordination of porphyrin molecules can significantly enhance the delivery efficacy of porphyrin photosensitizers to cancer cells [<xref rid="B5-pharmaceutics-17-00244" ref-type="bibr">5</xref>]. However, traditional metal&#x02013;porphyrin MOFs directly generate ROS upon light exposure, which cannot selectively target tumor tissues and may affect normal tissues. Therefore, developing a photo-inert porphyrin-based MOF formulation that only becomes phototherapeutically active in response to the tumor microenvironment is an essential area of study [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>].</p><p>For instance, Zhang et al. employed a one-pot synthesis method using Mn<sup>3+</sup> ions and TCPP as nodes and linker molecules to fabricate Mn-TCPP materials (<xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>A) [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>]. The resultant Mn-TCPP exhibits inert behavior; it remains quenched in fluorescence and incapable of ROS generation within normal tissue cells. Upon endocytosis by cancer cells, however, the Mn-TCPP interacts with the excess GSH inside these cells. The Mn<sup>3+</sup> ions are reduced to Mn<sup>2+</sup> ions, leading to the release of TCPP molecules into a free state. Under light irradiation, the released TCPP generates <sup>1</sup>O<sub>2</sub> that targets intracellular biomolecules, while GSH depletion facilitates ROS accumulation within the cell, thereby enhancing the PDT effect. Subsequent experiments revealed that the consumption of GSH increased significantly with higher concentrations of MOFs (<xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>B), and that the release of TCPP correspondingly increased with elevated GSH levels (<xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>C). The singlet oxygen sensing group (SOSG) assay confirmed that Mn-TCPP could be structurally disrupted by GSH, releasing TCPP and enabling the PDT process (<xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>D). As shown in <xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>D, the capacity for ROS production under light increased with rising GSH concentration up to 2.5 mM. Beyond this point, further increases in GSH concentration led to decreased ROS levels due to GSH&#x02019;s own ROS-scavenging ability. Considering the high concentration of GSH (up to 10 mM) in tumor cells, the authors tested the singlet-oxygen-generating capability of TCPP and Mn-TCPP in a 10 mM GSH solution. They found that Mn-TCPP generated twice as much singlet oxygen as free TCPP molecules under identical conditions (<xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>E). This result not only demonstrates the enhanced PDT mechanism of the Mn-TCPP system in response to intracellular GSH but also shows its effectiveness even at high GSH concentrations. The authors then evaluated the cytotoxicity of the material on different cell lines with varying GSH concentrations. The in vitro MTT assay, a commonly used method for evaluating the cytotoxicity of nanomedicines, was adopted by the authors to determine the therapeutic mechanism of Mn-TCPP under various conditions [<xref rid="B54-pharmaceutics-17-00244" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceutics-17-00244" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-17-00244" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-17-00244" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-17-00244" ref-type="bibr">58</xref>]. As depicted in <xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>F, compared with the normal 3T3 cell line, the cancer cell lines CT26, 4T1, and B16 showed increased cytotoxicity due to their relatively higher GSH levels. Additionally, the inclusion of a GSH synthesis inhibitor (L-buthionine sulfoximine, L-BSO) in cell cultures enhanced PDT efficacy as expected (<xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>G). Cytotoxicity assays (<xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>H) revealed that the MOFs plus light treatment group exhibited the lowest cell viability, demonstrating the strongest inhibition of cancer cell proliferation. Furthermore, <xref rid="pharmaceutics-17-00244-f003" ref-type="fig">Figure 3</xref>I illustrates that MOFs achieved optimal suppression of 4T1 cancer cell volume under 660 nm laser irradiation. Employing the Mn<sup>3+</sup> ion encapsulation strategy, this system achieves the controlled release of TCPP photosensitizer molecules in response to the GSH-rich microenvironment and enhances PDT efficacy by reducing GSH levels. It serves as a reference for developing safer and more reliable porphyrin-based MOF systems for phototherapy research, providing insights into improving the selective targeting of tumors while minimizing damage to healthy tissues. However, it should be noted that although the GSH depletion capability of nanomaterials can effectively enhance the efficacy of PDT, the hypoxic environment of solid tumor cells may still lead to a lower production of singlet oxygen, thereby resulting in suboptimal PDT effectiveness.</p></sec><sec id="sec5-pharmaceutics-17-00244"><title>5. MnFe<sub>2</sub>O<sub>4</sub>-Induced GSH Depletion for Enhanced PDT</title><p>Because cancers are known for their high lethality, the field of cancer treatment research has already consumed a considerable amount of researchers&#x02019; manpower and time investment [<xref rid="B59-pharmaceutics-17-00244" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceutics-17-00244" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-17-00244" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceutics-17-00244" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-17-00244" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-17-00244" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceutics-17-00244" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-17-00244" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-17-00244" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceutics-17-00244" ref-type="bibr">68</xref>]. Researchers have found that cancer cells exhibit unique characteristics such as hypoxic environments and elevated levels of reductive substances such as GSH, which significantly limit the efficacy of PDT, a process that relies on oxygen for its therapeutic action [<xref rid="B31-pharmaceutics-17-00244" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00244" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00244" ref-type="bibr">33</xref>]. To address this hypoxic microenvironment, researchers have adopted various strategies, such as using hemoglobin or perfluorocarbons to carry oxygen [<xref rid="B69-pharmaceutics-17-00244" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceutics-17-00244" ref-type="bibr">70</xref>], inhibiting mitochondrial respiration to directly cut off cellular oxygen consumption pathways [<xref rid="B71-pharmaceutics-17-00244" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-17-00244" ref-type="bibr">72</xref>,<xref rid="B73-pharmaceutics-17-00244" ref-type="bibr">73</xref>,<xref rid="B74-pharmaceutics-17-00244" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceutics-17-00244" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceutics-17-00244" ref-type="bibr">76</xref>], employing catalase to produce O<sub>2</sub> from H<sub>2</sub>O<sub>2</sub> [<xref rid="B77-pharmaceutics-17-00244" ref-type="bibr">77</xref>,<xref rid="B78-pharmaceutics-17-00244" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceutics-17-00244" ref-type="bibr">79</xref>,<xref rid="B80-pharmaceutics-17-00244" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceutics-17-00244" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceutics-17-00244" ref-type="bibr">82</xref>,<xref rid="B83-pharmaceutics-17-00244" ref-type="bibr">83</xref>], and utilizing Pt NPs or MnO<sub>2</sub> nanotechnology to catalyze O<sub>2</sub> generation from H<sub>2</sub>O<sub>2</sub> [<xref rid="B84-pharmaceutics-17-00244" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceutics-17-00244" ref-type="bibr">85</xref>,<xref rid="B86-pharmaceutics-17-00244" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceutics-17-00244" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceutics-17-00244" ref-type="bibr">88</xref>]. These studies underscore the importance of improving oxygen concentration for PDT. Research has also indicated that inorganic NPs such as Mn<sup>4+</sup> or Fe<sup>3+</sup> can effectively catalyze oxygen production from H<sub>2</sub>O<sub>2</sub> through a cyclic process. This Fenton-like reaction not only generates oxygen but also oxidizes GSH into GSSG in the presence of hydrogen peroxide, serving as a critical step to prevent reduced PDT efficacy. Moreover, these metal-based oxides are easily surface-modified and can form core&#x02013;shell structures, facilitating the preparation of composite materials combining inorganic oxides with porphyrin-based nMOFs. For example, Zhang et al. initially prepared polyvinylpyrrolidone (PVP)-coated MnFe<sub>2</sub>O<sub>4</sub> inorganic oxide particles, which were then used to adsorb Zr<sup>4+</sup> ions and tetracarboxylic acid porphyrins, resulting in the MnFe<sub>2</sub>O<sub>4</sub>@MOF nanocomposite (<xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>A) [<xref rid="B35-pharmaceutics-17-00244" ref-type="bibr">35</xref>]. This composite material enhances ROS concentration by concurrently increasing O<sub>2</sub> levels and depleting GSH, thereby potentiating PDT efficacy (<xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>A). Specifically, the authors first confirmed the O<sub>2</sub>-generating function of the material in the presence of H<sub>2</sub>O<sub>2</sub>. As shown in <xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>B, MnFe<sub>2</sub>O<sub>4</sub>@MOF efficiently produced O<sub>2</sub> when H<sub>2</sub>O<sub>2</sub> was present, whereas standalone Zr-TCPP MOF did not catalyze O<sub>2</sub> generation from H<sub>2</sub>O<sub>2</sub>. The peroxidase-like activity of MnFe<sub>2</sub>O<sub>4</sub> exhibited sustained effects, repeatedly catalyzing new additions of H<sub>2</sub>O<sub>2</sub> into O<sub>2</sub> (<xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>C). Subsequently, the authors verified the glutathione peroxidase-like activity of the prepared composite. As depicted in <xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>D, compared with the MOF treatment group, MnFe<sub>2</sub>O<sub>4</sub>@MOF significantly reduced GSH concentration, a process requiring H<sub>2</sub>O<sub>2</sub> participation (<xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>E). Importantly, experiments revealed that even under hypoxic conditions, MnFe<sub>2</sub>O<sub>4</sub>@MOF could effectively generate <sup>1</sup>O<sub>2</sub> upon light irradiation due to its intrinsic capability to catalyze O<sub>2</sub> production from H<sub>2</sub>O<sub>2</sub> (<xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>F), offering new opportunities for treating hypoxic tumors. Furthermore, it was found that more than fifty percent of the <sup>1</sup>O<sub>2</sub> generated by MOF alone was consumed by GSH post-irradiation (<xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>G). In contrast, less than 20% of the <sup>1</sup>O<sub>2</sub> produced by MnFe<sub>2</sub>O<sub>4</sub>@MOF was consumed by GSH, owing to the composite&#x02019;s autonomous GSH depletion function, which indeed contributed to increased intracellular ROS concentration (<xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>G). The authors demonstrated that MnFe<sub>2</sub>O<sub>4</sub>@MOF effectively reduced cell viability under both normoxic and hypoxic conditions when irradiated with 660 nm laser light (<xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>H,I). In vivo studies on mouse breast cancer 4T1 models showed that MnFe<sub>2</sub>O<sub>4</sub>@MOF significantly decreased tumor volume under light irradiation, indicating promising therapeutic outcomes (<xref rid="pharmaceutics-17-00244-f004" ref-type="fig">Figure 4</xref>J). This system successfully achieved autonomous O<sub>2</sub> generation and effective GSH reduction, enhancing PDT treatment efficacy. It offers new insights for therapies dependent on oxygen or GSH depletion, providing valuable references for the future biomedical applications and precise treatments of porphyrin-based nMOFs. This work presents an efficient approach to overcoming the limitations posed by the tumor microenvironment, significantly advancing the field of PDT. However, the system lacks active targeting functionality after administration, limiting its accumulation at the tumor site.</p></sec><sec id="sec6-pharmaceutics-17-00244"><title>6. Fe-TCPP nMOF-Induced GSH Depletion for Enhanced PDT</title><p>To enhance the targeting efficacy of porphyrin-based MOFs, surface modification is critical. Researchers have found that employing a biomimetic strategy by coating the MOF materials with cell membranes can effectively improve their targeting specificity towards cancer cells [<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>]. Additionally, encapsulating the NPs with hyaluronic acid (HA) can promote targeting to cancer cells that overexpress CD44 receptors on their surface [<xref rid="B89-pharmaceutics-17-00244" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceutics-17-00244" ref-type="bibr">90</xref>,<xref rid="B91-pharmaceutics-17-00244" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceutics-17-00244" ref-type="bibr">92</xref>]. For instance, Fan et al. first synthesized Fe-TCPP MOF NPs (FT NPs) and then utilized electrostatic interactions to modify their surface with HA polymer, resulting in FT@HA NPs (<xref rid="pharmaceutics-17-00244-f005" ref-type="fig">Figure 5</xref>A) [<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>]. The authors demonstrated that FT@HA NPs could be efficiently internalized by cells, achieving combined CDT initiated by Fe<sup>3+</sup> ions and enhanced PDT through GSH depletion. As shown in <xref rid="pharmaceutics-17-00244-f005" ref-type="fig">Figure 5</xref>B, the consumption of GSH increased with higher concentrations of FT@HA NPs and GSH. The authors verified that FT@HA NPs exhibited dual responsiveness to pH and GSH levels. At pH 5.5 and 10 mM GSH, the structural degradation of FT NPs was significantly enhanced, leading to the release of TCPP photosensitizer molecules (<xref rid="pharmaceutics-17-00244-f005" ref-type="fig">Figure 5</xref>C). This unique responsiveness to the intracellular environment of cancer cells minimizes damage to normal cells. Experimental results indicated that after treatment under conditions of pH 5.5 and 10 mM GSH, the singlet-oxygen-generation capacity of FT@HA NPs, as measured by ABDA assay, was notably increased (<xref rid="pharmaceutics-17-00244-f005" ref-type="fig">Figure 5</xref>D). The authors further evaluated the in vitro antitumor effects of the materials. As depicted in <xref rid="pharmaceutics-17-00244-f005" ref-type="fig">Figure 5</xref>E, due to their weak acidity and GSH responsiveness, FT@NPs exhibited mild cytotoxicity via Fenton reaction. Under light irradiation, the TCPP photosensitizer showed certain cytotoxicity. However, the FT@NPs treatment group demonstrated the lowest cell viability when activated by GSH and weak acidity. Moreover, the cellular uptake efficiency of different cells was examined. As shown in <xref rid="pharmaceutics-17-00244-f005" ref-type="fig">Figure 5</xref>F, since 4T1 cells overexpress CD44 receptors on their surface, they exhibited significantly higher uptake of FT@HA NPs compared with cells without overexpression of CD44 protein receptors. This indicates that surface modification with HA polymer enhances the active targeting effect of the material towards cancer cells. Consistent with the cytotoxicity results, the inhibition of 4T1 tumors in mice (<xref rid="pharmaceutics-17-00244-f005" ref-type="fig">Figure 5</xref>G) revealed that FT@HA NPs, when activated by intracellular weak acidity and GSH, exhibited effective suppression of tumor growth through the synergistic effects of PDT and CDT. This system provides new insights into the design of targeted therapies for porphyrin-based MOFs and microenvironment-responsive PDT strategies tailored to the pH and GSH characteristics of cancer cells. This work highlights the importance of surface modifications for enhancing the targeting capabilities of porphyrin-based MOFs. By leveraging the dual pH and GSH responsiveness, along with the active targeting properties provided by HA, the developed nanomaterials achieve improved therapeutic outcomes while minimizing off-target effects. This approach paves the way for more precise and effective cancer treatments. In this system, the author investigated the hydroxyl radicals generated by the Fenton-like system of Fe<sup>3+</sup>/H<sub>2</sub>O<sub>2</sub>. However, studies have shown that Fe<sup>3+</sup> disappears and forms Fe(OH)<sub>3</sub> precipitates when the pH is greater than 4. Therefore, strict acidic conditions (pH &#x0003c; 4) may be required for practical application. In contrast, the Cu<sup>2+</sup>/H<sub>2</sub>O<sub>2</sub> Fenton-like system can operate over a broader pH range [<xref rid="B93-pharmaceutics-17-00244" ref-type="bibr">93</xref>]. Therefore, investigating Fenton-like reactions based on Cu elements may lead to unexpected enhancements in the phototherapy effects of porphyrin-based nMOFs.</p></sec><sec id="sec7-pharmaceutics-17-00244"><title>7. Cu-MOF-Induced GSH Depletion for Enhanced PDT</title><p>In recent years, green gas therapy has emerged as a widely researched novel therapeutic approach [<xref rid="B94-pharmaceutics-17-00244" ref-type="bibr">94</xref>,<xref rid="B95-pharmaceutics-17-00244" ref-type="bibr">95</xref>,<xref rid="B96-pharmaceutics-17-00244" ref-type="bibr">96</xref>,<xref rid="B97-pharmaceutics-17-00244" ref-type="bibr">97</xref>]. This treatment modality primarily includes gases such as carbon monoxide (CO), nitric oxide (NO), sulfur dioxide (SO<sub>2</sub>), and hydrogen sulfide (H<sub>2</sub>S) [<xref rid="B98-pharmaceutics-17-00244" ref-type="bibr">98</xref>,<xref rid="B99-pharmaceutics-17-00244" ref-type="bibr">99</xref>,<xref rid="B100-pharmaceutics-17-00244" ref-type="bibr">100</xref>]. Among these, NO, acting as a free radical, exhibits dual functionalities: at low concentrations, it can prevent cell apoptosis and promote cancer cell metastasis; however, at higher concentrations, NO induces cell apoptosis through cytotoxic reactions or cellular organelle dysfunction, thereby demonstrating antitumor activity [<xref rid="B10-pharmaceutics-17-00244" ref-type="bibr">10</xref>]. Moreover, the NO gas could stimulate vasodilation which aids in restoring O<sub>2</sub> concentration and enhancing the efficacy of PDT [<xref rid="B37-pharmaceutics-17-00244" ref-type="bibr">37</xref>]. The integration of NO therapy with PDT has become a focal point of extensive research [<xref rid="B100-pharmaceutics-17-00244" ref-type="bibr">100</xref>]. Additionally, studies have shown that under weakly acidic conditions, the reaction rate between Cu<sup>2+</sup>/Cu<sup>+</sup> significantly increases compared with the transformation rate between Fe<sup>3+</sup>/Fe<sup>2+</sup> [<xref rid="B37-pharmaceutics-17-00244" ref-type="bibr">37</xref>]. Therefore, Cu-based Fenton reactions offer certain advantages over Fe-based systems. For example, Yuan et al. utilized Zr<sup>4+</sup> ions coordinated with TCPP to prepare MOF materials [<xref rid="B37-pharmaceutics-17-00244" ref-type="bibr">37</xref>]. Following this, they employed a straightforward ion-doping strategy to obtain Cu-MOF materials. They then conjugated NO donor-modified HA with the MOFs via electrostatic interactions, resulting in HN@Cu-MOF composite materials (<xref rid="pharmaceutics-17-00244-f006" ref-type="fig">Figure 6</xref>). HA facilitates the accumulation of nanomaterials in specific cancer cells rich in CD44 surface glycoproteins. Once inside the cells, the composite materials interact with intracellular GSH, not only depleting GSH levels but also releasing NO gas. Nitric oxide can react with ROS generated by light-activated materials to produce reactive nitrogen species (RNS). Through doping technology, the Cu<sup>2+</sup> ions within the composite material can interact with intracellular GSH to produce Cu<sup>+</sup> ions. Subsequently, the generated Cu<sup>+</sup> can react with intracellular H<sub>2</sub>O<sub>2</sub>, utilizing the Fenton-like reaction mechanism to produce highly oxidative hydroxyl radicals (<xref rid="pharmaceutics-17-00244-f006" ref-type="fig">Figure 6</xref>). This system effectively combines GSH depletion-enhanced NO gas therapy, PDT, and CDT for a potent inhibition of cancer cells. The simplicity and effectiveness of this system provide valuable insights into the application of porphyrin-based MOF materials. This work highlights the development of a multifunctional therapeutic platform that integrates NO release, ROS generation, and Cu<sup>+</sup>-mediated Fenton reactions. By leveraging the unique properties of Cu-based Fenton reactions and NO&#x02019;s dual role in promoting and inhibiting cancer progression, this study offers a promising strategy for enhancing the therapeutic efficacy of cancer treatments. It also provides a reference for future biomedical applications of porphyrin-based MOFs, emphasizing the importance of combining multiple therapeutic modalities to target the complex nature of cancer cells. In this system, the author investigated the enhancement of PDT effects of porphyrin-based nMOFs through the reaction of GSH-induced Cu<sup>+</sup> ions from Cu<sup>2+</sup> with H<sub>2</sub>O<sub>2</sub> in cancer cells to generate hydroxyl radicals. However, attention must be paid to the fact that Cu<sup>+</sup> ions are extremely susceptible to oxidation by O<sub>2</sub> into Cu<sup>2+</sup>, thereby inhibiting the Fenton-like reaction between Cu<sup>+</sup> and H<sub>2</sub>O<sub>2</sub> under slightly acidic conditions [<xref rid="B93-pharmaceutics-17-00244" ref-type="bibr">93</xref>].</p></sec><sec id="sec8-pharmaceutics-17-00244"><title>8. Fe(III)-Induced GSH Depletion for Enhanced PDT</title><p>PDT relies on the synergistic effects of photosensitizers, light sources, and oxygen [<xref rid="B53-pharmaceutics-17-00244" ref-type="bibr">53</xref>,<xref rid="B101-pharmaceutics-17-00244" ref-type="bibr">101</xref>]. While porphyrin-based MOFs significantly enhance the aqueous dispersion stability and tumor accumulation of hydrophobic photosensitizer molecules, their excitation wavelengths typically fall between 640 and 660 nm, limiting their effectiveness to superficial lesions and hindering penetration into deeper tissues. Consequently, for deep-seated tumors, the therapeutic efficacy of PDT may be suboptimal. Therefore, integrating two-photon or upconversion technologies with porphyrin-based photodynamic materials holds significant promise [<xref rid="B38-pharmaceutics-17-00244" ref-type="bibr">38</xref>]. Additionally, studies have shown that not only laser irradiation but also ultrasound can activate photosensitive materials to effectively generate ROS [<xref rid="B102-pharmaceutics-17-00244" ref-type="bibr">102</xref>,<xref rid="B103-pharmaceutics-17-00244" ref-type="bibr">103</xref>,<xref rid="B104-pharmaceutics-17-00244" ref-type="bibr">104</xref>,<xref rid="B105-pharmaceutics-17-00244" ref-type="bibr">105</xref>,<xref rid="B106-pharmaceutics-17-00244" ref-type="bibr">106</xref>,<xref rid="B107-pharmaceutics-17-00244" ref-type="bibr">107</xref>]. Based on this premise, Wang et al. employed a ligand exchange method to obtain PVP-coated UCNPs, followed by a one-pot synthesis at 90 &#x000b0;C for 5 h to develop a core&#x02013;shell structured composite material combining UCNPs with porphyrin-based MOFs, termed UPF (<xref rid="pharmaceutics-17-00244-f007" ref-type="fig">Figure 7</xref>) [<xref rid="B38-pharmaceutics-17-00244" ref-type="bibr">38</xref>]. They further modified the surface of this composite using biotin via amide bond chemistry, resulting in multifunctional UPFB composites. Biotin enhanced the targeting capability of the material towards HeLa cells and U14 tumor cells. After cellular internalization, an 808 nm upconversion mechanism was used to convert low-energy light into higher-energy UV&#x02013;visible light, which then activated the porphyrin photosensitizer to produce ROS. However, the authors noted that the energy transfer efficiency between the upconversion material and the porphyrin-based MOF in the UPF structure was relatively low. To address this issue, they incorporated SDT activation, utilizing ultrasound as an additional means to excite the photosensitive material. Furthermore, within the cell, Fe<sup>3+</sup> ions from Fe-MOF could undergo redox reactions with hydrogen peroxide, generating Fe<sup>2+</sup> ions and oxygen. The production of oxygen enhances ROS concentration during the PDT process (<xref rid="pharmaceutics-17-00244-f007" ref-type="fig">Figure 7</xref>). Moreover, Fe<sup>3+</sup> can react with the abundant reductive substance GSH within cancer cells, depleting GSH levels while generating Fe<sup>2+</sup> (<xref rid="pharmaceutics-17-00244-f007" ref-type="fig">Figure 7</xref>). This depletion facilitates the sustained presence and generation of high-concentration ROS, leading to cytotoxicity. In the weakly acidic intracellular environment, the generated Fe<sup>2+</sup> can further react with H<sub>2</sub>O<sub>2</sub> to form Fe<sup>3+</sup> and highly oxidative hydroxyl radicals, which are more potent than <sup>1</sup>O<sub>2</sub>. Thus, this system leverages 808 nm near-infrared light and ultrasound as coactivating energy sources, utilizing the catalase-like activity of Fe elements to increase O<sub>2</sub> concentration, intensify GSH depletion, and induce highly oxidative hydroxyl radicals through CDT. It achieves a combined therapeutic approach of PDT, CDT, and SDT, successfully inhibiting the proliferation of U14 tumor cells (<xref rid="pharmaceutics-17-00244-f007" ref-type="fig">Figure 7</xref>). This system provides new insights into enhancing PDT efficacy of porphyrin-based MOFs through GSH depletion, paving the way for advanced cancer treatments.</p></sec><sec id="sec9-pharmaceutics-17-00244"><title>9. MOF@Cu<sup>2+</sup>-Induced GSH Depletion for Enhanced PDT</title><p>GSH-enhanced PDT not only boosts the efficacy of porphyrin-based MOFs for solid tumor treatment but also holds significant promise for combating bacterial biofilm infections [<xref rid="B39-pharmaceutics-17-00244" ref-type="bibr">39</xref>]. Bacterial infections are a major cause of mortality each year, posing a substantial threat to human health [<xref rid="B39-pharmaceutics-17-00244" ref-type="bibr">39</xref>]. Bacteria protect themselves by secreting a polysaccharide matrix that shields them from external threats such as antibiotic treatments [<xref rid="B39-pharmaceutics-17-00244" ref-type="bibr">39</xref>]. Recent studies have demonstrated that PDT, a noninvasive and non-resistance-inducing therapy, is highly effective in inhibiting bacterial infections. Moreover, it has been found that bacterial biofilms contain considerable amounts of GSH. Reducing the level of GSH can prevent its consumption of ROS and continuously deplete the GSH leaked from bacteria, significantly enhancing the effectiveness of PDT. Therefore, developing an integrated therapeutic system that combines PDT with GSH depletion could offer a new and promising paradigm for anti-biofilm infection. For example, Shi et al. coordinated Zr<sup>4+</sup> ions with carboxyl groups of TCPP molecules to prepare Zr-TCPP MOF materials [<xref rid="B39-pharmaceutics-17-00244" ref-type="bibr">39</xref>]. Leveraging the large specific surface area of MOFs and the presence of free carboxyl groups, they facilitated the loading of other metal ions such as Cu<sup>2+</sup>. This resulted in the preparation of MOF@Cu<sup>2+</sup> composites (<xref rid="pharmaceutics-17-00244-f008" ref-type="fig">Figure 8</xref>A). Subsequent antibacterial experiments validated the effectiveness of this composite. The results showed that the loaded Cu<sup>2+</sup> ions could effectively interact with GSH within the bacterial biofilm. Under laser irradiation at 638 nm, the porphyrin photosensitizer-generated ROS to disrupt the bacterial biofilm, while the reduction of GSH by Cu<sup>2+</sup> minimized the biofilm&#x02019;s resistance to oxidative stress (<xref rid="pharmaceutics-17-00244-f008" ref-type="fig">Figure 8</xref>B). Furthermore, researchers demonstrated that Cu<sup>2+</sup> not only exhibits good biocompatibility but also promotes angiogenesis, thereby accelerating wound healing. The authors verified that the nanoplatform prepared in this system exhibited excellent antibacterial biofilm activity against Staphylococcus aureus both in vitro and in vivo (<xref rid="pharmaceutics-17-00244-f008" ref-type="fig">Figure 8</xref>B). This system not only provides a new approach for antimicrobial treatment and biofilm inhibition but also expands the phototherapeutic applications of porphyrin-based MOFs. It further substantiates that GSH depletion mechanisms can enhance PDT processes mediated by porphyrin-based MOFs.</p></sec><sec sec-type="conclusions" id="sec10-pharmaceutics-17-00244"><title>10. Conclusions</title><p>In recent decades, porphyrin-based nMOFs have garnered extensive attention due to their excellent biocompatibility and superior photochemical properties [<xref rid="B108-pharmaceutics-17-00244" ref-type="bibr">108</xref>,<xref rid="B109-pharmaceutics-17-00244" ref-type="bibr">109</xref>,<xref rid="B110-pharmaceutics-17-00244" ref-type="bibr">110</xref>]. The porphyrin-based nMOF therapeutic platform has become an effective drug delivery system for porphyrins and their derivatives, owing to its excellent stability and high photosensitizer loading capacity. A typical porphyrin-based nMOF comprises two main components: the porphyrin photosensitizer molecules and metal nodes. Much of the earlier research focused on the generation of <sup>1</sup>O<sub>2</sub> by porphyrin photosensitizers upon excitation by LED or laser light. As studies into the functionalization of metal ions and the tumor microenvironment have advanced, researchers have discovered that developing tumor microenvironment-responsive porphyrin-based MOFs through metal redox reactions can introduce new therapeutic mechanisms and significantly enhance PDT efficacy. For instance, multivalent metal ions such as Fe<sup>3+</sup>, Cu<sup>2+</sup>, and Mn<sup>3+</sup> can not only coordinate with TCPP to form MOF materials for efficient intracellular delivery of hydrophobic molecules but also leverage their variable valence states to react with the excess GSH in cancer cells [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00244" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00244" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-00244" ref-type="bibr">38</xref>]. This reaction reduces the metal ions while preventing GSH from scavenging ROS generated during the PDT process. This review summarizes how Cu<sup>2+</sup>-, Fe<sup>3+</sup>-, and Mn<sup>3+</sup>-coordinated porphyrin-based nMOFs exhibit enhanced PDT processes through GSH depletion within cancer cells. These studies have ingeniously utilized all functionalities of the MOFs&#x02019; metallic and TCPP components. They achieve modulation of MOF photoreactivity to minimize damage to normal cells and exploit GSH-induced MOF structure disruption for TCPP release, thereby enabling fluorescence imaging and enhanced photon utilization efficiency. Moreover, the reduced metal ions resulting from GSH-induced valence changes can provide MR imaging capabilities, ensuring reliable targeted drug delivery. This summary holds significant importance as it provides a theoretical foundation for the development and biomedical applications of multifunctional, tumor microenvironment-responsive porphyrin-based nMOFs.</p><p>Despite the significance of these research efforts, detailed studies remain relatively sparse, indicating ample room for further exploration in this field. There are still several issues that require additional investigation and discussion. For example, comparative studies on the reaction rates of different metals with GSH; whether targeting specific organelles, which may have varying GSH concentrations, could optimize GSH depletion; and the limitations of using 640&#x02013;660 nm wavelength light sources for treating deep-seated cancer cells. Additionally, some of the porphyrin-based MOFs discussed in this review require the framework to be disrupted to release metal ions for interaction with intracellular GSH, thereby facilitating its scavenging action. Consequently, highly stable porphyrin-based nMOFs may fail to participate in these reactions promptly due to their slower release rates. The large-scale production and clinical application of porphyrin-based nMOFs still face numerous challenges. In-depth research on their in vivo metabolic mechanisms is necessary to comprehensively evaluate their pharmacological and toxicological effects. Immunotherapy has been recognized as an effective approach for cancer treatment in recent years [<xref rid="B111-pharmaceutics-17-00244" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceutics-17-00244" ref-type="bibr">112</xref>,<xref rid="B113-pharmaceutics-17-00244" ref-type="bibr">113</xref>]. Given that GSH depletion itself may lead to changes in intracellular immune factors [<xref rid="B114-pharmaceutics-17-00244" ref-type="bibr">114</xref>], combining GSH depletion with immunotherapy and PDT could potentially yield unexpected therapeutic outcomes. Addressing these questions is crucial for enhancing the preclinical application potential of porphyrin-based MOFs.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>B.G.: writing&#x02014;original draft, writing&#x02014;review and editing. Q.Z.: writing&#x02014;original draft, writing&#x02014;review and editing. J.C.: writing&#x02014;original draft, writing&#x02014;review and editing. Y.Q.: writing&#x02014;original draft, writing&#x02014;review and editing. X.L.: writing&#x02014;original draft. W.W.: writing&#x02014;original draft, writing&#x02014;review and editing. X.Z.: funding acquisition, writing&#x02014;original draft, writing&#x02014;review and editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00244"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Junttila</surname><given-names>M.R.</given-names></name>
<name><surname>de Sauvage</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Influence of tumour micro-environment heterogeneity on therapeutic response</article-title><source>Nature</source><year>2013</year><volume>501</volume><fpage>346</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1038/nature12626</pub-id><pub-id pub-id-type="pmid">24048067</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00244"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Y.</given-names></name>
</person-group><article-title>Tumor microenvironment and cancer therapy resistance</article-title><source>Cancer Lett.</source><year>2016</year><volume>380</volume><fpage>205</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2015.07.044</pub-id><pub-id pub-id-type="pmid">26272180</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00244"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singleton</surname><given-names>D.C.</given-names></name>
<name><surname>Macann</surname><given-names>A.</given-names></name>
<name><surname>Wilson</surname><given-names>W.R.</given-names></name>
</person-group><article-title>Therapeutic targeting of the hypoxic tumour microenvironment</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2021</year><volume>18</volume><fpage>751</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1038/s41571-021-00539-4</pub-id><pub-id pub-id-type="pmid">34326502</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00244"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Tanani</surname><given-names>M.</given-names></name>
<name><surname>Rabbani</surname><given-names>S.A.</given-names></name>
<name><surname>Babiker</surname><given-names>R.</given-names></name>
<name><surname>Rangraze</surname><given-names>I.</given-names></name>
<name><surname>Kapre</surname><given-names>S.</given-names></name>
<name><surname>Palakurthi</surname><given-names>S.S.</given-names></name>
<name><surname>Alnuqaydan</surname><given-names>A.M.</given-names></name>
<name><surname>Aljabali</surname><given-names>A.A.</given-names></name>
<name><surname>Rizzo</surname><given-names>M.</given-names></name>
<name><surname>El-Tanani</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies</article-title><source>Cancer Lett.</source><year>2024</year><volume>591</volume><fpage>216894</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2024.216894</pub-id><pub-id pub-id-type="pmid">38626856</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00244"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Xia</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
</person-group><article-title>Recent progress of porphyrin metal&#x02013;organic frameworks for combined photodynamic therapy and hypoxia-activated chemotherapy</article-title><source>Chem. Commun.</source><year>2024</year><volume>60</volume><fpage>13641</fpage><lpage>13652</lpage><pub-id pub-id-type="doi">10.1039/D4CC04512B</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-00244"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>G.</given-names></name>
<name><surname>Chang</surname><given-names>J.-E.</given-names></name>
</person-group><article-title>Enhancing Cancer Treatment Through Combined Approaches: Photodynamic Therapy in Concert with Other Modalities</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>1420</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16111420</pub-id><pub-id pub-id-type="pmid">39598543</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00244"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Xie</surname><given-names>R.</given-names></name>
<name><surname>Yu</surname><given-names>T.</given-names></name>
</person-group><article-title>Photodynamic Therapy for Atherosclerosis: Past, Present, and Future</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>729</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16060729</pub-id><pub-id pub-id-type="pmid">38931851</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00244"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Porphyrin-based covalent organic framework nanoparticles for photoacoustic imaging-guided photodynamic and photothermal combination cancer therapy</article-title><source>Biomaterials</source><year>2019</year><volume>223</volume><elocation-id>119459</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119459</pub-id><pub-id pub-id-type="pmid">31499253</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00244"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Hao</surname><given-names>K.</given-names></name>
<name><surname>Tian</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Covalent Organic Nanosheets Integrated Heterojunction with Two Strategies to Overcome Hypoxic-Tumor Photodynamic Therapy</article-title><source>Chem. Mater.</source><year>2019</year><volume>31</volume><fpage>3313</fpage><lpage>3323</lpage><pub-id pub-id-type="doi">10.1021/acs.chemmater.9b00265</pub-id></element-citation></ref><ref id="B10-pharmaceutics-17-00244"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
</person-group><article-title>Photoactivatable nanogenerators of reactive species for cancer therapy</article-title><source>Bioact. Mater.</source><year>2021</year><volume>6</volume><fpage>4301</fpage><lpage>4318</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2021.04.030</pub-id><pub-id pub-id-type="pmid">33997507</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00244"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qi</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Qu</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
</person-group><article-title>Recent Advances in Porphyrin-Based Covalent Organic Frameworks for Synergistic Photodynamic and Photothermal Therapy</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>1625</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16121625</pub-id><pub-id pub-id-type="pmid">39771603</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00244"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheng</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Yan</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Tian</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Nanozyme-mediated cascade reaction based on metal-organic framework for synergetic chemo-photodynamic tumor therapy</article-title><source>J. Control. Release</source><year>2020</year><volume>328</volume><fpage>631</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.09.029</pub-id><pub-id pub-id-type="pmid">32950593</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00244"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Sheng</surname><given-names>S.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Bao</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>H.</given-names></name>
</person-group><article-title>Fe-TCPP@CS nanoparticles as photodynamic and photothermal agents for efficient antimicrobial therapy</article-title><source>Biomater. Sci.</source><year>2020</year><volume>8</volume><fpage>6526</fpage><lpage>6532</lpage><pub-id pub-id-type="doi">10.1039/D0BM01427C</pub-id><pub-id pub-id-type="pmid">33103167</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00244"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mariano</surname><given-names>S.</given-names></name>
<name><surname>Carata</surname><given-names>E.</given-names></name>
<name><surname>Calcagnile</surname><given-names>L.</given-names></name>
<name><surname>Panzarini</surname><given-names>E.</given-names></name>
</person-group><article-title>Recent Advances in Photodynamic Therapy: Metal-Based Nanoparticles as Tools to Improve Cancer Therapy</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>932</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16070932</pub-id><pub-id pub-id-type="pmid">39065629</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00244"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajaram</surname><given-names>J.</given-names></name>
<name><surname>Mende</surname><given-names>L.K.</given-names></name>
<name><surname>Kuthati</surname><given-names>Y.</given-names></name>
</person-group><article-title>A Review of the Efficacy of Nanomaterial-Based Natural Photosensitizers to Overcome Multidrug Resistance in Cancer</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>1120</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16091120</pub-id><pub-id pub-id-type="pmid">39339158</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00244"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hao</surname><given-names>K.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Sun</surname><given-names>P.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Atsushi</surname><given-names>M.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Tian</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Cationic Flexible Organic Framework for Combination of Photodynamic Therapy and Genetic Immunotherapy Against Tumors</article-title><source>Small</source><year>2021</year><volume>17</volume><fpage>2008125</fpage><pub-id pub-id-type="doi">10.1002/smll.202008125</pub-id></element-citation></ref><ref id="B17-pharmaceutics-17-00244"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ethirajan</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Joshi</surname><given-names>P.</given-names></name>
<name><surname>Pandey</surname><given-names>R.K.</given-names></name>
</person-group><article-title>The role of porphyrin chemistry in tumor imaging and photodynamic therapy</article-title><source>Chem. Soc. Rev.</source><year>2011</year><volume>40</volume><fpage>340</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1039/B915149B</pub-id><pub-id pub-id-type="pmid">20694259</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00244"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>B.</given-names></name>
<name><surname>Nawaz</surname><given-names>M.H.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
</person-group><article-title>Recent advances of multi-dimensional porphyrin-based functional materials in photodynamic therapy</article-title><source>Coord. Chem. Rev.</source><year>2020</year><volume>420</volume><fpage>213410</fpage><pub-id pub-id-type="doi">10.1016/j.ccr.2020.213410</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-00244"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Kaskel</surname><given-names>S.</given-names></name>
</person-group><article-title>Porphyrin-Based Metal&#x02013;Organic Frameworks for Biomedical Applications</article-title><source>Angew. Chem. Int. Ed.</source><year>2021</year><volume>60</volume><fpage>5010</fpage><lpage>5035</lpage><pub-id pub-id-type="doi">10.1002/anie.201909880</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-00244"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>J.-F.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
</person-group><article-title>A Bacteria-Responsive Porphyrin for Adaptable Photodynamic/Photothermal Therapy</article-title><source>Angew. Chem. Int. Ed.</source><year>2022</year><volume>61</volume><fpage>e202200799</fpage><pub-id pub-id-type="doi">10.1002/anie.202200799</pub-id></element-citation></ref><ref id="B21-pharmaceutics-17-00244"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>D.</given-names></name>
<name><surname>Duan</surname><given-names>Q.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Dong</surname><given-names>W.</given-names></name>
</person-group><article-title>Photodynamic therapy based on porphyrin-based metal&#x02013;organic frameworks</article-title><source>J. Mater. Chem. B</source><year>2023</year><volume>11</volume><fpage>5976</fpage><lpage>5989</lpage><pub-id pub-id-type="doi">10.1039/D2TB02789E</pub-id><pub-id pub-id-type="pmid">37310273</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00244"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>B.</given-names></name>
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
</person-group><article-title>Advancements of Porphyrin-Derived Nanomaterials for Antibacterial Photodynamic Therapy and Biofilm Eradication</article-title><source>Adv. Healthc. Mater.</source><year>2024</year><volume>13</volume><fpage>2401211</fpage><pub-id pub-id-type="doi">10.1002/adhm.202401211</pub-id><pub-id pub-id-type="pmid">39073000</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00244"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Luo</surname><given-names>X.</given-names></name>
<name><surname>Qu</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Xia</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
</person-group><article-title>Porphyrin-engineered nanoscale metal-organic frameworks: Enhancing photodynamic therapy and ferroptosis in oncology</article-title><source>Front. Pharmacol.</source><year>2024</year><volume>15</volume><elocation-id>1481168</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2024.1481168</pub-id><pub-id pub-id-type="pmid">39512824</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00244"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Luo</surname><given-names>X.</given-names></name>
<name><surname>Qu</surname><given-names>Y.</given-names></name>
<name><surname>Xia</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
</person-group><article-title>Recent advances in cell membrane-coated porphyrin-based nanoscale MOFs for enhanced photodynamic therapy</article-title><source>Front. Pharmacol.</source><year>2024</year><volume>15</volume><elocation-id>1505212</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2024.1505212</pub-id><pub-id pub-id-type="pmid">39697550</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00244"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>J.-J.</given-names></name>
<name><surname>Lei</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>X.-Z.</given-names></name>
</person-group><article-title>Recent advances in photonanomedicines for enhanced cancer photodynamic therapy</article-title><source>Prog. Mater. Sci.</source><year>2020</year><volume>114</volume><fpage>100685</fpage><pub-id pub-id-type="doi">10.1016/j.pmatsci.2020.100685</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-00244"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Cheng</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Zeng</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.-Z.</given-names></name>
</person-group><article-title>Near infrared light-triggered metal ion and photodynamic therapy based on AgNPs/porphyrinic MOFs for tumors and pathogens elimination</article-title><source>Biomaterials</source><year>2020</year><volume>248</volume><elocation-id>120029</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120029</pub-id><pub-id pub-id-type="pmid">32289589</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00244"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>B.-R.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.-H.</given-names></name>
<name><surname>Zeng</surname><given-names>J.-Y.</given-names></name>
<name><surname>Zou</surname><given-names>M.-Z.</given-names></name>
<name><surname>Li</surname><given-names>C.-X.</given-names></name>
<name><surname>Zeng</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.-Z.</given-names></name>
</person-group><article-title>A near infrared ratiometric platform based &#x003c0;-extended porphyrin metal-organic framework for O<sub>2</sub> imaging and cancer therapy</article-title><source>Biomaterials</source><year>2021</year><volume>272</volume><elocation-id>120782</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120782</pub-id><pub-id pub-id-type="pmid">33819816</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00244"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Xie</surname><given-names>B.-R.</given-names></name>
<name><surname>Liu</surname><given-names>X.-H.</given-names></name>
<name><surname>Ye</surname><given-names>J.-J.</given-names></name>
<name><surname>Zhong</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>X.-Z.</given-names></name>
</person-group><article-title>Mineralized Porphyrin Metal&#x02013;Organic Framework for Improved Tumor Elimination and Combined Immunotherapy</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>12471</fpage><lpage>12482</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c02126</pub-id><pub-id pub-id-type="pmid">37364286</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00244"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Yeung</surname><given-names>K.W.K.</given-names></name>
<name><surname>Cui</surname><given-names>Z.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
</person-group><article-title>The recent progress on metal&#x02013;organic frameworks for phototherapy</article-title><source>Chem. Soc. Rev.</source><year>2021</year><volume>50</volume><fpage>5086</fpage><lpage>5125</lpage><pub-id pub-id-type="doi">10.1039/D1CS00056J</pub-id><pub-id pub-id-type="pmid">33634817</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00244"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Kuang</surname><given-names>Y.</given-names></name>
<name><surname>Gulzar</surname><given-names>A.</given-names></name>
<name><surname>He</surname><given-names>F.</given-names></name>
<name><surname>Gai</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>P.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
</person-group><article-title>Recent advances in porphyrin-based MOFs for cancer therapy and diagnosis therapy</article-title><source>Coord. Chem. Rev.</source><year>2021</year><volume>439</volume><fpage>213945</fpage><pub-id pub-id-type="doi">10.1016/j.ccr.2021.213945</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-00244"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>Y.</given-names></name>
<name><surname>Xiao</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
</person-group><article-title>Engineering nanomedicine for glutathione depletion-augmented cancer therapy</article-title><source>Chem. Soc. Rev.</source><year>2021</year><volume>50</volume><fpage>6013</fpage><lpage>6041</lpage><pub-id pub-id-type="doi">10.1039/D0CS00718H</pub-id><pub-id pub-id-type="pmid">34027953</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00244"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>H.-D.</given-names></name>
<name><surname>Ran</surname><given-names>H.-H.</given-names></name>
<name><surname>Liang</surname><given-names>G.</given-names></name>
<name><surname>Wu</surname><given-names>F.-G.</given-names></name>
</person-group><article-title>Glutathione-Depleting Nanomedicines for Synergistic Cancer Therapy</article-title><source>ACS Nano</source><year>2021</year><volume>15</volume><fpage>8039</fpage><lpage>8068</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c00498</pub-id><pub-id pub-id-type="pmid">33974797</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00244"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>B.</given-names></name>
<name><surname>Liao</surname><given-names>K.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Wen</surname><given-names>T.</given-names></name>
<name><surname>Quan</surname><given-names>G.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
</person-group><article-title>Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy</article-title><source>Biomaterials</source><year>2021</year><volume>277</volume><elocation-id>121110</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121110</pub-id><pub-id pub-id-type="pmid">34482088</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00244"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wan</surname><given-names>S.-S.</given-names></name>
<name><surname>Cheng</surname><given-names>Q.</given-names></name>
<name><surname>Zeng</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.-Z.</given-names></name>
</person-group><article-title>A Mn(III)-Sealed Metal&#x02013;Organic Framework Nanosystem for Redox-Unlocked Tumor Theranostics</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><fpage>6561</fpage><lpage>6571</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b00300</pub-id><pub-id pub-id-type="pmid">31136707</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00244"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>S.-Y.</given-names></name>
<name><surname>Song</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Zhu</surname><given-names>L.-M.</given-names></name>
<name><surname>Yin</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.-B.</given-names></name>
</person-group><article-title>Persistent Regulation of Tumor Microenvironment via Circulating Catalysis of MnFe<sub>2</sub>O<sub>4</sub>@Metal&#x02013;Organic Frameworks for Enhanced Photodynamic Therapy</article-title><source>Adv. Funct. Mater.</source><year>2019</year><volume>29</volume><fpage>1901417</fpage><pub-id pub-id-type="doi">10.1002/adfm.201901417</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-00244"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Dai</surname><given-names>Y.</given-names></name>
<name><surname>Kong</surname><given-names>Y.</given-names></name>
<name><surname>Du</surname><given-names>W.</given-names></name>
<name><surname>Ni</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Shen</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Fan</surname><given-names>Q.</given-names></name>
</person-group><article-title>Tumor Microenvironment-Responsive Fe(III)&#x02013;Porphyrin Nanotheranostics for Tumor Imaging and Targeted Chemodynamic&#x02013;Photodynamic Therapy</article-title><source>ACS Appl. Mater. Interfaces</source><year>2020</year><volume>12</volume><fpage>53634</fpage><lpage>53645</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c14046</pub-id><pub-id pub-id-type="pmid">33205657</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00244"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Yan</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wen</surname><given-names>J.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
</person-group><article-title>All-in-one HN@Cu-MOF nanoparticles with enhanced reactive oxygen species generation and GSH depletion for effective tumor treatment</article-title><source>J. Mater. Chem. B</source><year>2023</year><volume>11</volume><fpage>11519</fpage><lpage>11531</lpage><pub-id pub-id-type="doi">10.1039/D3TB02433D</pub-id><pub-id pub-id-type="pmid">38047895</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00244"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Feng</surname><given-names>L.</given-names></name>
<name><surname>He</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>P.</given-names></name>
<name><surname>Gai</surname><given-names>S.</given-names></name>
<name><surname>Quan</surname><given-names>Z.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
</person-group><article-title>Upconverted Metal&#x02013;Organic Framework Janus Architecture for Near-Infrared and Ultrasound Co-Enhanced High Performance Tumor Therapy</article-title><source>ACS Nano</source><year>2021</year><volume>15</volume><fpage>12342</fpage><lpage>12357</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c04280</pub-id><pub-id pub-id-type="pmid">34160201</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00244"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Wei</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Copper(ii)-infused porphyrin MOF: Maximum scavenging GSH for enhanced photodynamic disruption of bacterial biofilm</article-title><source>J. Mater. Chem. B</source><year>2024</year><volume>12</volume><fpage>1317</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1039/D3TB02577B</pub-id><pub-id pub-id-type="pmid">38229564</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00244"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>C.</given-names></name>
<name><surname>Ding</surname><given-names>S.</given-names></name>
<name><surname>Jiang</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>F.-B.</given-names></name>
</person-group><article-title>Glutathione-depleting nanoplatelets for enhanced sonodynamic cancer therapy</article-title><source>Nanoscale</source><year>2021</year><volume>13</volume><fpage>4512</fpage><lpage>4518</lpage><pub-id pub-id-type="doi">10.1039/D0NR08440A</pub-id><pub-id pub-id-type="pmid">33615325</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00244"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Ji</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Xia</surname><given-names>R.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
</person-group><article-title>Nutrient vitamins enabled metabolic regulation of ferroptosis via reactive oxygen species biology</article-title><source>Front. Pharmacol.</source><year>2024</year><volume>15</volume><elocation-id>1434088</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2024.1434088</pub-id><pub-id pub-id-type="pmid">39092216</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00244"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>J.-Q.</given-names></name>
<name><surname>Assaraf</surname><given-names>Y.G.</given-names></name>
<name><surname>Ren</surname><given-names>L.</given-names></name>
<name><surname>Gupta</surname><given-names>P.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
<name><surname>Ashby</surname><given-names>C.R.</given-names></name>
<name><surname>Yang</surname><given-names>D.-H.</given-names></name>
<name><surname>Chen</surname><given-names>Z.-S.</given-names></name>
</person-group><article-title>Modulating ROS to overcome multidrug resistance in cancer</article-title><source>Drug Resist. Updates</source><year>2018</year><volume>41</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2018.11.001</pub-id><pub-id pub-id-type="pmid">30471641</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00244"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>D.-Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Su</surname><given-names>G.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
</person-group><article-title>Polymer-metal-organic framework hybrids for bioimaging and cancer therapy</article-title><source>Coord. Chem. Rev.</source><year>2022</year><volume>456</volume><fpage>214393</fpage><pub-id pub-id-type="doi">10.1016/j.ccr.2021.214393</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-00244"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Shang</surname><given-names>M.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
</person-group><article-title>Two-dimensional metal-organic frameworks: From synthesis to bioapplications</article-title><source>J. Nanobiotechnol.</source><year>2022</year><volume>20</volume><elocation-id>207</elocation-id><pub-id pub-id-type="doi">10.1186/s12951-022-01395-9</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-00244"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>K.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Mao</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>L.</given-names></name>
<name><surname>Geng</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Luo</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Multienzyme-like Reactivity Cooperatively Impairs Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways in Triple-Negative Breast Cancer for Sensitized Ferroptosis Therapy</article-title><source>ACS Nano</source><year>2022</year><volume>16</volume><fpage>2381</fpage><lpage>2398</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c08664</pub-id><pub-id pub-id-type="pmid">35041395</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00244"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Cao</surname><given-names>F.</given-names></name>
<name><surname>Ruan</surname><given-names>Y.</given-names></name>
<name><surname>Jia</surname><given-names>X.</given-names></name>
<name><surname>Zhen</surname><given-names>W.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
</person-group><article-title>Specific Generation of Singlet Oxygen through the Russell Mechanism in Hypoxic Tumors and GSH Depletion by Cu-TCPP Nanosheets for Cancer Therapy</article-title><source>Angew. Chem. Int. Ed.</source><year>2019</year><volume>58</volume><fpage>9846</fpage><lpage>9850</lpage><pub-id pub-id-type="doi">10.1002/anie.201903981</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-00244"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Deng</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Guo</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Dai</surname><given-names>P.</given-names></name>
<name><surname>Fan</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Triggered All-Active Metal Organic Framework: Ferroptosis Machinery Contributes to the Apoptotic Photodynamic Antitumor Therapy</article-title><source>Nano Lett.</source><year>2019</year><volume>19</volume><fpage>7866</fpage><lpage>7876</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b02904</pub-id><pub-id pub-id-type="pmid">31594301</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00244"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>He</surname><given-names>H.</given-names></name>
<name><surname>Jiao</surname><given-names>P.</given-names></name>
<name><surname>Han</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
</person-group><article-title>Metal&#x02013;Organic Framework for Hypoxia/ROS/pH Triple-Responsive Cargo Release</article-title><source>Adv. Healthc. Mater.</source><year>2023</year><volume>12</volume><fpage>2301785</fpage><pub-id pub-id-type="doi">10.1002/adhm.202301785</pub-id></element-citation></ref><ref id="B49-pharmaceutics-17-00244"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Shi</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>K.-J.</given-names></name>
<name><surname>Ditty</surname><given-names>M.M.</given-names></name>
<name><surname>Xing</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>H.-Z.</given-names></name>
<name><surname>Ren</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>S.-Y.</given-names></name>
</person-group><article-title>Nanoscale coordination polymers enabling antioxidants inhibition for enhanced chemodynamic therapy</article-title><source>J. Control. Release</source><year>2023</year><volume>354</volume><fpage>196</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.01.004</pub-id><pub-id pub-id-type="pmid">36610480</pub-id>
</element-citation></ref><ref id="B50-pharmaceutics-17-00244"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Dong</surname><given-names>S.</given-names></name>
<name><surname>Kuang</surname><given-names>Y.</given-names></name>
<name><surname>Dong</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>F.</given-names></name>
<name><surname>Gai</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>P.</given-names></name>
</person-group><article-title>Fusiform-Like Copper(II)-Based Metal&#x02013;Organic Framework through Relief Hypoxia and GSH-Depletion Co-Enhanced Starvation and Chemodynamic Synergetic Cancer Therapy</article-title><source>ACS Appl. Mater. Interfaces</source><year>2020</year><volume>12</volume><fpage>17254</fpage><lpage>17267</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c01539</pub-id><pub-id pub-id-type="pmid">32227859</pub-id>
</element-citation></ref><ref id="B51-pharmaceutics-17-00244"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Z.</given-names></name>
<name><surname>Liang</surname><given-names>S.</given-names></name>
<name><surname>Cai</surname><given-names>X.</given-names></name>
<name><surname>Ding</surname><given-names>B.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Hou</surname><given-names>Z.</given-names></name>
<name><surname>Ma</surname><given-names>P.A.</given-names></name>
<name><surname>Cheng</surname><given-names>Z.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
</person-group><article-title>O<sub>2</sub>-Cu/ZIF-8@Ce6/ZIF-8@F127 Composite as a Tumor Microenvironment-Responsive Nanoplatform with Enhanced Photo-/Chemodynamic Antitumor Efficacy</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>31671</fpage><lpage>31680</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b10685</pub-id><pub-id pub-id-type="pmid">31397149</pub-id>
</element-citation></ref><ref id="B52-pharmaceutics-17-00244"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Q.</given-names></name>
<name><surname>Zhan</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Yong</surname><given-names>T.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Gan</surname><given-names>L.</given-names></name>
</person-group><article-title>Manganese porphyrin-based metal-organic framework for synergistic sonodynamic therapy and ferroptosis in hypoxic tumors</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>1937</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.7150/thno.45511</pub-id><pub-id pub-id-type="pmid">33408790</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00244"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Lei</surname><given-names>P.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
</person-group><article-title>Nanoscale Mixed-Component Metal&#x02013;Organic Frameworks with Photosensitizer Spatial-Arrangement-Dependent Photochemistry for Multimodal-Imaging-Guided Photothermal Therapy</article-title><source>Chem. Mater.</source><year>2018</year><volume>30</volume><fpage>6867</fpage><lpage>6876</lpage><pub-id pub-id-type="doi">10.1021/acs.chemmater.8b03043</pub-id></element-citation></ref><ref id="B54-pharmaceutics-17-00244"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
</person-group><article-title>Chitosan nanoparticles for oral photothermally enhanced photodynamic therapy of colon cancer</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>589</volume><fpage>119763</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119763</pub-id><pub-id pub-id-type="pmid">32898629</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00244"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Han</surname><given-names>G.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Dong</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
</person-group><article-title>Au-Pt Nanoparticle Formulation as a Radiosensitizer for Radiotherapy with Dual Effects</article-title><source>Int. J. Nanomed.</source><year>2021</year><volume>16</volume><fpage>239</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.2147/IJN.S287523</pub-id></element-citation></ref><ref id="B56-pharmaceutics-17-00244"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
</person-group><article-title>M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1493</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13091493</pub-id><pub-id pub-id-type="pmid">34575569</pub-id>
</element-citation></ref><ref id="B57-pharmaceutics-17-00244"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Tu</surname><given-names>M.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Meng</surname><given-names>G.</given-names></name>
<name><surname>Gu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Inhibition of fucosylation by 2-fluorofucose attenuated acetaminophen-induced liver injury via its anti-inflammation and anti-oxidative stress effects</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><elocation-id>939317</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.939317</pub-id><pub-id pub-id-type="pmid">36120347</pub-id>
</element-citation></ref><ref id="B58-pharmaceutics-17-00244"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yapeng</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Rui</surname><given-names>C.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
</person-group><article-title>2, 4, 5-Trideoxyhexopyranosides Derivatives of 4&#x02032;-Demethylepipodophyllotoxin: De novo Synthesis and Anticancer Activity</article-title><source>Med. Chem.</source><year>2022</year><volume>18</volume><fpage>130</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.2174/1573406416666201120102250</pub-id><pub-id pub-id-type="pmid">33222676</pub-id>
</element-citation></ref><ref id="B59-pharmaceutics-17-00244"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bao</surname><given-names>L.</given-names></name>
<name><surname>Zhong</surname><given-names>J.</given-names></name>
<name><surname>Pang</surname><given-names>L.</given-names></name>
</person-group><article-title>Upregulation of Circular RNA VPS13C-has-circ-001567 Promotes Ovarian Cancer Cell Proliferation and Invasion</article-title><source>Cancer Biother. Radiopharm.</source><year>2018</year><volume>34</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1089/cbr.2018.2641</pub-id><pub-id pub-id-type="pmid">30376358</pub-id>
</element-citation></ref><ref id="B60-pharmaceutics-17-00244"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Su</surname><given-names>G.</given-names></name>
<name><surname>Yin</surname><given-names>X.</given-names></name>
<name><surname>Luo</surname><given-names>J.</given-names></name>
<name><surname>Gu</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Feng</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
</person-group><article-title>Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor&#x02014;Afatinib: In vitro and in vivo evaluation</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>120</volume><elocation-id>109493</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109493</pub-id><pub-id pub-id-type="pmid">31586902</pub-id>
</element-citation></ref><ref id="B61-pharmaceutics-17-00244"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>X.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Shen</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Hao</surname><given-names>H.</given-names></name>
<name><surname>Gu</surname><given-names>Y.</given-names></name>
</person-group><article-title>RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma</article-title><source>Int. Immunopharmacol.</source><year>2020</year><volume>87</volume><fpage>106707</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106707</pub-id><pub-id pub-id-type="pmid">32683297</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00244"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>P.</given-names></name>
<name><surname>He</surname><given-names>D.</given-names></name>
<name><surname>Xu</surname><given-names>B.</given-names></name>
<name><surname>Tu</surname><given-names>J.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Long-Circulating Thermosensitive Liposomes for the Targeted Drug Delivery of Oxaliplatin</article-title><source>Int. J. Nanomed.</source><year>2020</year><volume>15</volume><fpage>6721</fpage><lpage>6734</lpage><pub-id pub-id-type="doi">10.2147/IJN.S250773</pub-id><pub-id pub-id-type="pmid">32982229</pub-id>
</element-citation></ref><ref id="B63-pharmaceutics-17-00244"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Song</surname><given-names>R.</given-names></name>
<name><surname>Lu</surname><given-names>P.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Shen</surname><given-names>G.</given-names></name>
<name><surname>Jiang</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
</person-group><article-title>A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy</article-title><source>Int. J. Nanomed.</source><year>2020</year><volume>15</volume><fpage>65</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.2147/IJN.S230237</pub-id></element-citation></ref><ref id="B64-pharmaceutics-17-00244"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Gu</surname><given-names>C.</given-names></name>
<name><surname>Gan</surname><given-names>Y.</given-names></name>
<name><surname>Shao</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
</person-group><article-title>Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis</article-title><source>J. Control. Release</source><year>2020</year><volume>318</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.12.005</pub-id><pub-id pub-id-type="pmid">31830541</pub-id>
</element-citation></ref><ref id="B65-pharmaceutics-17-00244"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jie</surname><given-names>Z.</given-names></name>
<name><surname>Qianqian</surname><given-names>S.</given-names></name>
<name><surname>Mengna</surname><given-names>W.</given-names></name>
<name><surname>Wenjie</surname><given-names>Z.</given-names></name>
</person-group><article-title>The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma</article-title><source>Curr. Med. Chem.</source><year>2021</year><volume>28</volume><fpage>93</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.2174/0929867327666200130103206</pub-id><pub-id pub-id-type="pmid">32000636</pub-id>
</element-citation></ref><ref id="B66-pharmaceutics-17-00244"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karaosmanoglu</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Shi</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Williams</surname><given-names>G.R.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Carrier-free nanodrugs for safe and effective cancer treatment</article-title><source>J. Control. Release</source><year>2021</year><volume>329</volume><fpage>805</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.10.014</pub-id><pub-id pub-id-type="pmid">33045313</pub-id>
</element-citation></ref><ref id="B67-pharmaceutics-17-00244"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lusha</surname><given-names>Z.</given-names></name>
<name><surname>Mei</surname><given-names>L.</given-names></name>
</person-group><article-title>The Synthesis of Nano-Doxorubicin and its Anticancer Effect</article-title><source>Anti-Cancer Agents Med. Chem.</source><year>2021</year><volume>21</volume><fpage>2466</fpage><lpage>2477</lpage><pub-id pub-id-type="doi">10.2174/1871520621666201229115612</pub-id></element-citation></ref><ref id="B68-pharmaceutics-17-00244"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Han</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
<name><surname>Fan</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>2D materials for bone therapy</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>178</volume><fpage>113970</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.113970</pub-id><pub-id pub-id-type="pmid">34509576</pub-id>
</element-citation></ref><ref id="B69-pharmaceutics-17-00244"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wrobeln</surname><given-names>A.</given-names></name>
<name><surname>J&#x000e4;gers</surname><given-names>J.</given-names></name>
<name><surname>Quinting</surname><given-names>T.</given-names></name>
<name><surname>Schreiber</surname><given-names>T.</given-names></name>
<name><surname>Kirsch</surname><given-names>M.</given-names></name>
<name><surname>Fandrey</surname><given-names>J.</given-names></name>
<name><surname>Ferenz</surname><given-names>K.B.</given-names></name>
</person-group><article-title>Albumin-derived perfluorocarbon-based artificial oxygen carriers can avoid hypoxic tissue damage in massive hemodilution</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>11950</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-68701-z</pub-id><pub-id pub-id-type="pmid">32686717</pub-id>
</element-citation></ref><ref id="B70-pharmaceutics-17-00244"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ye</surname><given-names>Q.</given-names></name>
<name><surname>Zheng</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>K.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
</person-group><article-title>Research Progress in Oxygen Carrier Design and Application</article-title><source>Mol. Pharm.</source><year>2023</year><volume>20</volume><fpage>4373</fpage><lpage>4386</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00289</pub-id><pub-id pub-id-type="pmid">37579000</pub-id>
</element-citation></ref><ref id="B71-pharmaceutics-17-00244"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wen</surname><given-names>J.</given-names></name>
<name><surname>Luo</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Shang</surname><given-names>T.</given-names></name>
<name><surname>Zhou</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Mitochondria-targeted nanoplatforms for enhanced photodynamic therapy against hypoxia tumor</article-title><source>J. Nanobiotechnol.</source><year>2021</year><volume>19</volume><elocation-id>440</elocation-id><pub-id pub-id-type="doi">10.1186/s12951-021-01196-6</pub-id><pub-id pub-id-type="pmid">34930284</pub-id>
</element-citation></ref><ref id="B72-pharmaceutics-17-00244"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>J.-Q.</given-names></name>
<name><surname>Zhao</surname><given-names>L.-P.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>L.-S.</given-names></name>
<name><surname>Zheng</surname><given-names>R.-R.</given-names></name>
<name><surname>Deng</surname><given-names>F.-A.</given-names></name>
<name><surname>Liu</surname><given-names>Y.-B.</given-names></name>
<name><surname>Yu</surname><given-names>X.-Y.</given-names></name>
<name><surname>Li</surname><given-names>S.-Y.</given-names></name>
<name><surname>Cheng</surname><given-names>H.</given-names></name>
</person-group><article-title>Carrier Free O<sub>2</sub>-Economizer for Photodynamic Therapy Against Hypoxic Tumor by Inhibiting Cell Respiration</article-title><source>Small</source><year>2022</year><volume>18</volume><fpage>2107467</fpage><pub-id pub-id-type="doi">10.1002/smll.202107467</pub-id><pub-id pub-id-type="pmid">35224854</pub-id>
</element-citation></ref><ref id="B73-pharmaceutics-17-00244"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cen</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>B.</given-names></name>
<name><surname>Yan</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>N.</given-names></name>
<name><surname>Kong</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Ti</surname><given-names>H.</given-names></name>
<name><surname>Cheng</surname><given-names>H.</given-names></name>
</person-group><article-title>Drug induced mitochondria dysfunction to enhance photodynamic therapy of hypoxic tumors</article-title><source>J. Control Release</source><year>2023</year><volume>358</volume><fpage>654</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.05.023</pub-id><pub-id pub-id-type="pmid">37209961</pub-id>
</element-citation></ref><ref id="B74-pharmaceutics-17-00244"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Wei</surname><given-names>Z.</given-names></name>
<name><surname>Fan</surname><given-names>G.</given-names></name>
<name><surname>Wan</surname><given-names>F.</given-names></name>
<name><surname>Tian</surname><given-names>L.</given-names></name>
</person-group><article-title>Ultra-stable MOF@MOF nanoplatform for photodynamic therapy sensitized by relieved hypoxia due to mitochondrial respiration inhibition</article-title><source>Acta Biomater.</source><year>2023</year><volume>170</volume><fpage>330</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2023.08.025</pub-id><pub-id pub-id-type="pmid">37607616</pub-id>
</element-citation></ref><ref id="B75-pharmaceutics-17-00244"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Lv</surname><given-names>B.</given-names></name>
<name><surname>Xue</surname><given-names>G.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Cao</surname><given-names>J.</given-names></name>
</person-group><article-title>Smart Nanosystem-Mediated Inhibition of Mitochondrial Respiration for Enhanced Phototherapy-Induced Antitumor Immunity</article-title><source>Int. J. Nanomed.</source><year>2023</year><volume>18</volume><fpage>3443</fpage><lpage>3457</lpage><pub-id pub-id-type="doi">10.2147/IJN.S413204</pub-id></element-citation></ref><ref id="B76-pharmaceutics-17-00244"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>G.</given-names></name>
<name><surname>Tillman</surname><given-names>L.</given-names></name>
<name><surname>Luo</surname><given-names>T.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>Fan</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>G.</given-names></name>
<name><surname>Lin</surname><given-names>W.</given-names></name>
</person-group><article-title>Nanoscale Metal-Organic Layer Reprograms Cellular Metabolism to Enhance Photodynamic Therapy and Antitumor Immunity</article-title><source>Angew. Chem. Int. Ed.</source><year>2024</year><volume>63</volume><fpage>e202410241</fpage><pub-id pub-id-type="doi">10.1002/anie.202410241</pub-id></element-citation></ref><ref id="B77-pharmaceutics-17-00244"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>L.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Fang</surname><given-names>Q.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Xue</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>R.</given-names></name>
</person-group><article-title>Oxygen-producing catalase-based prodrug nanoparticles overcoming resistance in hypoxia-mediated chemo-photodynamic therapy</article-title><source>Acta Biomater.</source><year>2020</year><volume>112</volume><fpage>234</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2020.05.035</pub-id><pub-id pub-id-type="pmid">32502633</pub-id>
</element-citation></ref><ref id="B78-pharmaceutics-17-00244"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Yao</surname><given-names>Q.</given-names></name>
<name><surname>Shao</surname><given-names>K.</given-names></name>
<name><surname>Xu</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>N.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Catalase-based liposomal for reversing immunosuppressive tumor microenvironment and enhanced cancer chemo-photodynamic therapy</article-title><source>Biomaterials</source><year>2020</year><volume>233</volume><elocation-id>119755</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.119755</pub-id><pub-id pub-id-type="pmid">31927233</pub-id>
</element-citation></ref><ref id="B79-pharmaceutics-17-00244"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>R.</given-names></name>
<name><surname>Ohulchanskyy</surname><given-names>T.Y.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Ziniuk</surname><given-names>R.</given-names></name>
<name><surname>Qu</surname><given-names>J.</given-names></name>
</person-group><article-title>Catalase Nanocrystals Loaded with Methylene Blue as Oxygen Self-Supplied, Imaging-Guided Platform for Photodynamic Therapy of Hypoxic Tumors</article-title><source>Small</source><year>2021</year><volume>17</volume><fpage>2103569</fpage><pub-id pub-id-type="doi">10.1002/smll.202103569</pub-id></element-citation></ref><ref id="B80-pharmaceutics-17-00244"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dan</surname><given-names>Q.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
<name><surname>Zheng</surname><given-names>S.</given-names></name>
<name><surname>Ma</surname><given-names>H.</given-names></name>
<name><surname>Luo</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Su</surname><given-names>N.</given-names></name>
<name><surname>Hu</surname><given-names>D.</given-names></name>
<name><surname>Sheng</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>Gold Nanoclusters-Based NIR-II Photosensitizers with Catalase-like Activity for Boosted Photodynamic Therapy</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1645</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14081645</pub-id><pub-id pub-id-type="pmid">36015272</pub-id>
</element-citation></ref><ref id="B81-pharmaceutics-17-00244"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
</person-group><article-title>Self-Assembly Catalase Nanocomplex Conveyed by Bacterial Vesicles for Oxygenated Photodynamic Therapy and Tumor Immunotherapy</article-title><source>Int. J. Nanomed.</source><year>2022</year><volume>17</volume><fpage>1971</fpage><lpage>1985</lpage><pub-id pub-id-type="doi">10.2147/IJN.S353330</pub-id><pub-id pub-id-type="pmid">35530972</pub-id>
</element-citation></ref><ref id="B82-pharmaceutics-17-00244"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sim</surname><given-names>Y.</given-names></name>
<name><surname>Seong</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Choi</surname><given-names>E.</given-names></name>
<name><surname>Lah</surname><given-names>M.S.</given-names></name>
<name><surname>Ryu</surname><given-names>J.-H.</given-names></name>
</person-group><article-title>Metal&#x02013;Organic Framework-Supported Catalase Delivery for Enhanced Photodynamic Therapy via Hypoxia Mitigation</article-title><source>ACS Appl. Mater. Interfaces</source><year>2023</year><volume>15</volume><fpage>50953</fpage><lpage>50961</lpage><pub-id pub-id-type="doi">10.1021/acsami.3c13395</pub-id><pub-id pub-id-type="pmid">37883653</pub-id>
</element-citation></ref><ref id="B83-pharmaceutics-17-00244"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Jia</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Catalase-Conjugated Rose Bengal Biological Nanoparticles with Mitochondrial Selectivity Toward Photodynamic Therapy</article-title><source>CCS Chem.</source><year>2023</year><volume>5</volume><fpage>2877</fpage><lpage>2887</lpage><pub-id pub-id-type="doi">10.31635/ccschem.023.202202525</pub-id></element-citation></ref><ref id="B84-pharmaceutics-17-00244"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Jia</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>D.</given-names></name>
<name><surname>He</surname><given-names>F.</given-names></name>
<name><surname>Gai</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>P.</given-names></name>
</person-group><article-title>Self-generation of oxygen and simultaneously enhancing photodynamic therapy and MRI effect: An intelligent nanoplatform to conquer tumor hypoxia for enhanced phototherapy</article-title><source>Chem. Eng. J.</source><year>2020</year><volume>390</volume><fpage>124624</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2020.124624</pub-id></element-citation></ref><ref id="B85-pharmaceutics-17-00244"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wen</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>K.</given-names></name>
<name><surname>Sun</surname><given-names>S.</given-names></name>
</person-group><article-title>MnO<sub>2</sub>-Based nanosystems for cancer therapy</article-title><source>Chem. Commun.</source><year>2020</year><volume>56</volume><fpage>7065</fpage><lpage>7079</lpage><pub-id pub-id-type="doi">10.1039/D0CC02782K</pub-id></element-citation></ref><ref id="B86-pharmaceutics-17-00244"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>S.-B.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Jiang</surname><given-names>N.</given-names></name>
</person-group><article-title>MnO<sub>2</sub>-coated porous Pt@CeO<sub>2</sub> core&#x02013;shell nanostructures for photoacoustic imaging-guided tri-modal cancer therapy</article-title><source>Nanoscale</source><year>2021</year><volume>13</volume><fpage>16499</fpage><lpage>16508</lpage><pub-id pub-id-type="doi">10.1039/D1NR03246A</pub-id><pub-id pub-id-type="pmid">34585196</pub-id>
</element-citation></ref><ref id="B87-pharmaceutics-17-00244"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Gui</surname><given-names>T.</given-names></name>
<name><surname>Song</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>C.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Ge</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
</person-group><article-title>Metal&#x02013;Organic Framework PCN-224 Integrated with Manganese Dioxide, Platinum Nanoparticles, and Glucose Oxidase for Enhanced Cancer Chemodynamic Therapy</article-title><source>ACS Appl. Nano Mater.</source><year>2023</year><volume>6</volume><fpage>7446</fpage><lpage>7455</lpage><pub-id pub-id-type="doi">10.1021/acsanm.3c00610</pub-id></element-citation></ref><ref id="B88-pharmaceutics-17-00244"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Feng</surname><given-names>X.</given-names></name>
<name><surname>Han</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
</person-group><article-title>MnO<sub>2</sub>-based bioresponsive nanoplatform synergizing mitochondrial metabolism modulation for amplified phototherapy and chemodynamic therapy of melanoma</article-title><source>Chem. Eng. J.</source><year>2025</year><volume>504</volume><fpage>158757</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2024.158757</pub-id></element-citation></ref><ref id="B89-pharmaceutics-17-00244"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spadea</surname><given-names>A.</given-names></name>
<name><surname>Rios de la Rosa</surname><given-names>J.M.</given-names></name>
<name><surname>Tirella</surname><given-names>A.</given-names></name>
<name><surname>Ashford</surname><given-names>M.B.</given-names></name>
<name><surname>Williams</surname><given-names>K.J.</given-names></name>
<name><surname>Stratford</surname><given-names>I.J.</given-names></name>
<name><surname>Tirelli</surname><given-names>N.</given-names></name>
<name><surname>Mehibel</surname><given-names>M.</given-names></name>
</person-group><article-title>Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44</article-title><source>Mol. Pharm.</source><year>2019</year><volume>16</volume><fpage>2481</fpage><lpage>2493</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00083</pub-id><pub-id pub-id-type="pmid">31013093</pub-id>
</element-citation></ref><ref id="B90-pharmaceutics-17-00244"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soleymani</surname><given-names>M.</given-names></name>
<name><surname>Velashjerdi</surname><given-names>M.</given-names></name>
<name><surname>Asgari</surname><given-names>M.</given-names></name>
</person-group><article-title>Preparation of hyaluronic acid-decorated mixed nanomicelles for targeted delivery of hydrophobic drugs to CD44-overexpressing cancer cells</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>592</volume><fpage>120052</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.120052</pub-id><pub-id pub-id-type="pmid">33159986</pub-id>
</element-citation></ref><ref id="B91-pharmaceutics-17-00244"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Heo</surname><given-names>R.</given-names></name>
<name><surname>Song</surname><given-names>S.H.</given-names></name>
<name><surname>Song</surname><given-names>K.-H.</given-names></name>
<name><surname>Shin</surname><given-names>J.M.</given-names></name>
<name><surname>Oh</surname><given-names>S.J.</given-names></name>
<name><surname>Lee</surname><given-names>H.-J.</given-names></name>
<name><surname>Chung</surname><given-names>J.E.</given-names></name>
<name><surname>Park</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>T.W.</given-names></name>
</person-group><article-title>PD-L1 siRNA&#x02013;hyaluronic acid conjugate for dual-targeted cancer immunotherapy</article-title><source>J. Control. Release</source><year>2022</year><volume>346</volume><fpage>226</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.04.023</pub-id><pub-id pub-id-type="pmid">35461969</pub-id>
</element-citation></ref><ref id="B92-pharmaceutics-17-00244"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ouyang</surname><given-names>Q.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>K.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Qin</surname><given-names>M.</given-names></name>
</person-group><article-title>Hyaluronic Acid Receptor-Mediated Nanomedicines and Targeted Therapy</article-title><source>Small Methods</source><year>2024</year><volume>8</volume><fpage>2400513</fpage><pub-id pub-id-type="doi">10.1002/smtd.202400513</pub-id><pub-id pub-id-type="pmid">39039982</pub-id>
</element-citation></ref><ref id="B93-pharmaceutics-17-00244"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bokare</surname><given-names>A.D.</given-names></name>
<name><surname>Choi</surname><given-names>W.</given-names></name>
</person-group><article-title>Review of iron-free Fenton-like systems for activating H<sub>2</sub>O<sub>2</sub> in advanced oxidation processes</article-title><source>J. Hazard. Mater.</source><year>2014</year><volume>275</volume><fpage>121</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.jhazmat.2014.04.054</pub-id><pub-id pub-id-type="pmid">24857896</pub-id>
</element-citation></ref><ref id="B94-pharmaceutics-17-00244"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Fu</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Fan</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>G.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Mao</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Ultra-efficient Antibacterial System Based on Photodynamic Therapy and CO Gas Therapy for Synergistic Antibacterial and Ablation Biofilms</article-title><source>ACS Appl. Mater. Interfaces</source><year>2020</year><volume>12</volume><fpage>22479</fpage><lpage>22491</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c01967</pub-id><pub-id pub-id-type="pmid">32329344</pub-id>
</element-citation></ref><ref id="B95-pharmaceutics-17-00244"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Xia</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Rong</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Su</surname><given-names>Z.</given-names></name>
<name><surname>Zeng</surname><given-names>X.</given-names></name>
<name><surname>Du</surname><given-names>J.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>A Glutathione Activatable Photosensitizer for Combined Photodynamic and Gas Therapy under Red Light Irradiation</article-title><source>Adv. Healthc. Mater.</source><year>2022</year><volume>11</volume><fpage>2102017</fpage><pub-id pub-id-type="doi">10.1002/adhm.202102017</pub-id></element-citation></ref><ref id="B96-pharmaceutics-17-00244"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Jin</surname><given-names>L.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
</person-group><article-title>Strategic Design of Conquering Hypoxia in Tumor for Advanced Photodynamic Therapy</article-title><source>Adv. Healthc. Mater.</source><year>2023</year><volume>12</volume><fpage>2300530</fpage><pub-id pub-id-type="doi">10.1002/adhm.202300530</pub-id></element-citation></ref><ref id="B97-pharmaceutics-17-00244"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Suo</surname><given-names>M.</given-names></name>
<name><surname>Lyu</surname><given-names>M.</given-names></name>
<name><surname>Lam</surname><given-names>J.W.Y.</given-names></name>
<name><surname>Jin</surname><given-names>Z.</given-names></name>
<name><surname>Ning</surname><given-names>S.</given-names></name>
<name><surname>Tang</surname><given-names>B.Z.</given-names></name>
</person-group><article-title>Photothermal-Triggered Sulfur Oxide Gas Therapy Augments Type I Photodynamic Therapy for Potentiating Cancer Stem Cell Ablation and Inhibiting Radioresistant Tumor Recurrence</article-title><source>Adv. Sci.</source><year>2023</year><volume>10</volume><fpage>2304042</fpage><pub-id pub-id-type="doi">10.1002/advs.202304042</pub-id></element-citation></ref><ref id="B98-pharmaceutics-17-00244"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Cao</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Deng</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><article-title>Gas-assisted phototherapy for cancer treatment</article-title><source>J. Control Release</source><year>2023</year><volume>360</volume><fpage>564</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.07.015</pub-id><pub-id pub-id-type="pmid">37442200</pub-id>
</element-citation></ref><ref id="B99-pharmaceutics-17-00244"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>L.</given-names></name>
<name><surname>Zhou</surname><given-names>B.</given-names></name>
<name><surname>Qi</surname><given-names>M.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Dong</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Dong</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
</person-group><article-title>A coating strategy on titanium implants with enhanced photodynamic therapy and CO-based gas therapy for bacterial killing and inflammation regulation</article-title><source>Chin. Chem. Lett.</source><year>2024</year><volume>35</volume><fpage>108648</fpage><pub-id pub-id-type="doi">10.1016/j.cclet.2023.108648</pub-id></element-citation></ref><ref id="B100-pharmaceutics-17-00244"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Guan</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><article-title>Current trends in gas-synergized phototherapy for improved antitumor theranostics</article-title><source>Acta Biomater.</source><year>2024</year><volume>174</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2023.12.012</pub-id><pub-id pub-id-type="pmid">38092250</pub-id>
</element-citation></ref><ref id="B101-pharmaceutics-17-00244"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Pei</surname><given-names>Q.</given-names></name>
<name><surname>He</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
</person-group><article-title>Metal&#x02013;Organic Framework@Porous Organic Polymer Nanocomposite for Photodynamic Therapy</article-title><source>Chem. Mater.</source><year>2017</year><volume>29</volume><fpage>2374</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1021/acs.chemmater.7b00228</pub-id></element-citation></ref><ref id="B102-pharmaceutics-17-00244"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ayala</surname><given-names>E.T.P.</given-names></name>
<name><surname>de Sousa</surname><given-names>F.A.D.</given-names></name>
<name><surname>Vollet-Filho</surname><given-names>J.D.</given-names></name>
<name><surname>Garcia</surname><given-names>M.R.</given-names></name>
<name><surname>De Boni</surname><given-names>L.</given-names></name>
<name><surname>Bagnato</surname><given-names>V.S.</given-names></name>
<name><surname>Pratavieira</surname><given-names>S.</given-names></name>
</person-group><article-title>Photodynamic and Sonodynamic Therapy with Protoporphyrin IX: In Vitro and In Vivo Studies</article-title><source>Ultrasound Med. Biol.</source><year>2021</year><volume>47</volume><fpage>1032</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1016/j.ultrasmedbio.2020.12.006</pub-id><pub-id pub-id-type="pmid">33446374</pub-id>
</element-citation></ref><ref id="B103-pharmaceutics-17-00244"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Gong</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>P.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Dong</surname><given-names>H.</given-names></name>
</person-group><article-title>ROS-Activated nanoscale coordination polymers for enhanced ultrasound-mediated therapy for the treatment of cancer</article-title><source>Acta Biomater.</source><year>2022</year><volume>143</volume><fpage>372</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2022.02.030</pub-id><pub-id pub-id-type="pmid">35219868</pub-id>
</element-citation></ref><ref id="B104-pharmaceutics-17-00244"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deng</surname><given-names>C.</given-names></name>
<name><surname>Zheng</surname><given-names>M.</given-names></name>
<name><surname>Han</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xin</surname><given-names>J.</given-names></name>
<name><surname>Aras</surname><given-names>O.</given-names></name>
<name><surname>Cheng</surname><given-names>L.</given-names></name>
<name><surname>An</surname><given-names>F.</given-names></name>
</person-group><article-title>GSH-Activated Porphyrin Sonosensitizer Prodrug for Fluorescence Imaging-Guided Cancer Sonodynamic Therapy</article-title><source>Adv. Funct. Mater.</source><year>2023</year><volume>33</volume><fpage>2300348</fpage><pub-id pub-id-type="doi">10.1002/adfm.202300348</pub-id><pub-id pub-id-type="pmid">38045635</pub-id>
</element-citation></ref><ref id="B105-pharmaceutics-17-00244"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<name><surname>Cao</surname><given-names>W.</given-names></name>
</person-group><article-title>Multifunctional Porphyrin-Based Sonosensitizers for Sonodynamic Therapy</article-title><source>Adv. Funct. Mater.</source><year>2024</year><volume>34</volume><fpage>2405844</fpage><pub-id pub-id-type="doi">10.1002/adfm.202405844</pub-id></element-citation></ref><ref id="B106-pharmaceutics-17-00244"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das</surname><given-names>M.</given-names></name>
<name><surname>Pandey</surname><given-names>V.</given-names></name>
<name><surname>Jajoria</surname><given-names>K.</given-names></name>
<name><surname>Bhatia</surname><given-names>D.</given-names></name>
<name><surname>Gupta</surname><given-names>I.</given-names></name>
<name><surname>Shekhar</surname><given-names>H.</given-names></name>
</person-group><article-title>Glycosylated Porphyrin Derivatives for Sonodynamic Therapy: ROS Generation and Cytotoxicity Studies in Breast Cancer Cells</article-title><source>ACS Omega</source><year>2024</year><volume>9</volume><fpage>1196</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1021/acsomega.3c07445</pub-id><pub-id pub-id-type="pmid">38222585</pub-id>
</element-citation></ref><ref id="B107-pharmaceutics-17-00244"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Meng</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Ma</surname><given-names>P.A.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
</person-group><article-title>Engineered Metal&#x02013;Organic Framework with Stereotactic Anchoring and Spatial Separation of Porphyrins for Amplified Ultrasound-Mediated Pyroptosis and Cancer Immunotherapy</article-title><source>Angew. Chem. Int. Ed.</source><year>2024</year><fpage>e202421402</fpage><pub-id pub-id-type="doi">10.1002/anie.202421402</pub-id></element-citation></ref><ref id="B108-pharmaceutics-17-00244"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Shen</surname><given-names>W.</given-names></name>
<name><surname>Jiang</surname><given-names>Q.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Yin</surname><given-names>D.</given-names></name>
</person-group><article-title>Engineering a curcumol-loaded porphyrinic metal-organic framework for enhanced cancer photodynamic therapy</article-title><source>Colloids Surf. B Biointerfaces</source><year>2022</year><volume>214</volume><elocation-id>112456</elocation-id><pub-id pub-id-type="doi">10.1016/j.colsurfb.2022.112456</pub-id><pub-id pub-id-type="pmid">35290822</pub-id>
</element-citation></ref><ref id="B109-pharmaceutics-17-00244"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
<name><surname>Dang</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Tian</surname><given-names>Y.</given-names></name>
</person-group><article-title>Porphyrin-based metal&#x02014;Organic framework nanocrystals for combination of immune and sonodynamic therapy</article-title><source>Nano Res.</source><year>2023</year><volume>16</volume><fpage>9633</fpage><lpage>9641</lpage><pub-id pub-id-type="doi">10.1007/s12274-023-5477-5</pub-id></element-citation></ref><ref id="B110-pharmaceutics-17-00244"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>S.</given-names></name>
<name><surname>Xiang</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Pei</surname><given-names>R.</given-names></name>
</person-group><article-title>Research development of porphyrin-based metal&#x02013;organic frameworks: Targeting modalities and cancer therapeutic applications</article-title><source>J. Mater. Chem. B</source><year>2023</year><volume>11</volume><fpage>6172</fpage><lpage>6200</lpage><pub-id pub-id-type="doi">10.1039/D3TB00632H</pub-id><pub-id pub-id-type="pmid">37305964</pub-id>
</element-citation></ref><ref id="B111-pharmaceutics-17-00244"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
</person-group><article-title>The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis</article-title><source>Int. Immunopharmacol.</source><year>2020</year><volume>88</volume><fpage>106966</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106966</pub-id><pub-id pub-id-type="pmid">33182067</pub-id>
</element-citation></ref><ref id="B112-pharmaceutics-17-00244"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Yao</surname><given-names>D.</given-names></name>
<name><surname>Ye</surname><given-names>T.</given-names></name>
<name><surname>Yao</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1</article-title><source>Acta Pharm. Sin. B</source><year>2020</year><volume>10</volume><fpage>1943</fpage><lpage>1953</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2020.02.010</pub-id><pub-id pub-id-type="pmid">33163345</pub-id>
</element-citation></ref><ref id="B113-pharmaceutics-17-00244"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mao</surname><given-names>L.</given-names></name>
<name><surname>Yin</surname><given-names>M.</given-names></name>
<name><surname>Ji</surname><given-names>C.</given-names></name>
<name><surname>Ma</surname><given-names>Q.</given-names></name>
<name><surname>Xia</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
</person-group><article-title>Targeted delivery of T-cell agonists for enhancing immunotherapy</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2023</year><volume>89</volume><fpage>105074</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2023.105074</pub-id></element-citation></ref><ref id="B114-pharmaceutics-17-00244"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perricone</surname><given-names>C.</given-names></name>
<name><surname>De Carolis</surname><given-names>C.</given-names></name>
<name><surname>Perricone</surname><given-names>R.</given-names></name>
</person-group><article-title>Glutathione: A key player in autoimmunity</article-title><source>Autoimmun. Rev.</source><year>2009</year><volume>8</volume><fpage>697</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2009.02.020</pub-id><pub-id pub-id-type="pmid">19393193</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00244-f001"><label>Figure 1</label><caption><p>Schematic illustration of the synthesis of porphyrin-based nMOFs, the redox reaction activity of metal ions within their framework, and their biomedical functions. Additionally, this figure explains the mechanism by which nMOFs exhibit enhanced PDT efficacy following GSH depletion. Reproduced with permission from [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00244" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00244" ref-type="bibr">37</xref>]. Copyright (2019), American Chemical Society (Washington, DC, USA). Copyright (2019), John Wiley &#x00026; Sons, Ltd. (Hoboken, NJ, USA). Copyright (2020), American Chemical Society (Washington, DC, USA). Copyright (2023), The Royal Society of Chemistry (Cambridge, UK).</p></caption><graphic xlink:href="pharmaceutics-17-00244-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00244-f002"><label>Figure 2</label><caption><p>(<bold>A</bold>) The molecular structure of GSH and its reaction with ROS or metal ions to form GSSG. (<bold>B</bold>) Schematic illustration of Cu<sup>2+</sup> coordination with TCPP to form the Cu-TCPP MOF. (<bold>C</bold>) Illustration of Zr<sup>4+</sup> coordination with TCPP molecules to form the Zr-TCPP MOF, and its subsequent loading with Cu<sup>2+</sup> ions. (<bold>D</bold>) Schematic representation of Zr-TCPP MOF growth on the surface of inorganic oxides or UCNPs.</p></caption><graphic xlink:href="pharmaceutics-17-00244-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00244-f003"><label>Figure 3</label><caption><p>(<bold>A</bold>) Schematic illustration of the preparation of Mn(III)-TCPP nMOFs and their in vivo GSH-responsive depletion, followed by activation of fluorescence imaging and MRI-guided enhanced PDT therapy. (<bold>B</bold>) The effect of varying amounts of MOF material on the consumption of GSH at different concentrations. (<bold>C</bold>) The effect of different GSH concentrations on the release of TCPP molecules from MOFs. (<bold>D</bold>) ROS-generation ability detected by SOSG. (<bold>E</bold>) TCPP and MOF-induced ROS-generation ability (10 mM GSH). *** <italic toggle="yes">p</italic> &#x0003c; 0.001. (<bold>F</bold>) The cell viability of Mn-TCPP MOFs against four cell lines. (<bold>G</bold>) Cell viability under different incubation conditions (TCPP + hv, TCPP + L-BSO + hv). ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001. (<bold>H</bold>) Cell viability after treatment with four incubation conditions. ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001. (<bold>I</bold>) Tumor volume changes from different groups after 14 days. *** <italic toggle="yes">p</italic> &#x0003c; 0.001. Reproduced with permission from [<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>]. Copyright (2019), American Chemical Society.</p></caption><graphic xlink:href="pharmaceutics-17-00244-g003" position="float"/></fig><fig position="float" id="pharmaceutics-17-00244-f004"><label>Figure 4</label><caption><p>(<bold>A</bold>) Synthesis procedure of MnFe<sub>2</sub>O<sub>4</sub>@MOF@PEG composite material. (<bold>B</bold>) Comparison of O<sub>2</sub> generation by MOF and MnFe<sub>2</sub>O<sub>4</sub>@MOF materials after H<sub>2</sub>O<sub>2</sub> addition. (<bold>C</bold>) Comparison of O<sub>2</sub> generation by MOF and MnFe<sub>2</sub>O<sub>4</sub>@MOF materials after three additions of H<sub>2</sub>O<sub>2</sub>. (<bold>D</bold>) Comparison of GSH consumption by different concentrations of MOF and MnFe<sub>2</sub>O<sub>4</sub>@MOF materials. (<bold>E</bold>) Variations in GSH levels under three different conditions. (<bold>F</bold>) Comparison of <sup>1</sup>O<sub>2</sub> generation by MOF and MnFe<sub>2</sub>O<sub>4</sub>@MOF materials under hypoxic conditions. (<bold>G</bold>) Comparison of <sup>1</sup>O<sub>2</sub>-generation capacity after treatment under four different conditions (using SOSG as a <sup>1</sup>O<sub>2</sub> scavenger). (<bold>H</bold>) Comparison of cell viability following treatment under four distinct conditions in normoxic conditions. (** <italic toggle="yes">p</italic> &#x0003c; 0.01 and *** <italic toggle="yes">p</italic> &#x0003c; 0.001). (<bold>I</bold>) Comparison of cell viability following treatment under four distinct conditions in hypoxia conditions (* <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01). (<bold>J</bold>) Changes in relative tumor volume in mice under six different conditions (** <italic toggle="yes">p</italic> &#x0003c; 0.01 and *** <italic toggle="yes">p</italic> &#x0003c; 0.001). Reproduced with permission from [<xref rid="B35-pharmaceutics-17-00244" ref-type="bibr">35</xref>]. Copyright (2019), John Wiley &#x00026; Sons, Ltd.</p></caption><graphic xlink:href="pharmaceutics-17-00244-g004" position="float"/></fig><fig position="float" id="pharmaceutics-17-00244-f005"><label>Figure 5</label><caption><p>(<bold>A</bold>) Schematic illustration of the preparation of FT@HA NPs and their in vivo synergistic antitumor mechanism. (<bold>B</bold>) The effect of different concentrations of FT@HA NPs on the consumption of GSH at varying concentrations. (<bold>C</bold>) TCPP release from FT@HA NPs triggered by pH and GSH. (<bold>D</bold>) <sup>1</sup>O<sub>2</sub>-generation capability of FT@HA NPs under different pH and GSH concentration conditions (with ABDA as a <sup>1</sup>O<sub>2</sub> scavenger). (<bold>E</bold>) Comparison of the viability of 4T1 cells following treatment under three distinct conditions. (<bold>F</bold>) Assessment of cell viability in 4T1 and NIH-3T3 cells after exposure to FT@HA NPs. ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001. (<bold>G</bold>) Tumor volume changes after different treatments. Reproduced with permission from [<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>]. Copyright (2020), American Chemical Society.</p></caption><graphic xlink:href="pharmaceutics-17-00244-g005" position="float"/></fig><fig position="float" id="pharmaceutics-17-00244-f006"><label>Figure 6</label><caption><p>An overview of the fabrication procedure for HN@Cu-MOF and a schematic depiction of its therapeutic functions in PDT, CDT, and NO gas therapy. Reproduced with permission from [<xref rid="B37-pharmaceutics-17-00244" ref-type="bibr">37</xref>]. Copyright (2023), The Royal Society of Chemistry.</p></caption><graphic xlink:href="pharmaceutics-17-00244-g006" position="float"/></fig><fig position="float" id="pharmaceutics-17-00244-f007"><label>Figure 7</label><caption><p>Schematic illustration of the composition of UPFB NPs and their antitumor mechanisms activated by 808 nm laser irradiation and ultrasound. Reproduced with permission from [<xref rid="B38-pharmaceutics-17-00244" ref-type="bibr">38</xref>]. Copyright (2021), American Chemical Society.</p></caption><graphic xlink:href="pharmaceutics-17-00244-g007" position="float"/></fig><fig position="float" id="pharmaceutics-17-00244-f008"><label>Figure 8</label><caption><p>(<bold>A</bold>) Schematic illustration of the synthesis procedure for MOF@Cu<sup>2+</sup>. (<bold>B</bold>) Schematic illustration of how released Cu<sup>2+</sup> enhances PDT antibacterial activity of MOF materials under 638 nm light by depleting GSH in bacterial biofilms. Reproduced with permission from [<xref rid="B39-pharmaceutics-17-00244" ref-type="bibr">39</xref>]. Copyright (2024), The Royal Society of Chemistry.</p></caption><graphic xlink:href="pharmaceutics-17-00244-g008" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00244-t001"><object-id pub-id-type="pii">pharmaceutics-17-00244-t001_Table 1</object-id><label>Table 1</label><caption><p>Synthesis of nMOFs and their GSH depletion mechanisms for enhanced antitumor applications.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Material</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Structure</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">GSH Depletion Mechanism/Therapeutic Advantages</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Refs</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porphyrin</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoscale MOF</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> for GSH <break/> depletion <break/> Au/Cu-TCPP(Fe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i001.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i002.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Au &#x02192; glucose depletion &#x02192; reduced GSH biosynthesis, <break/> Cu<sup>2+</sup> + GSG &#x02192; Cu<sup>+</sup> + GSSG, <break/> Ferroptosis therapy,</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-pharmaceutics-17-00244" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> for GSH <break/> depletion <break/> 2D Cu-TCPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i003.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i004.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> + GSG &#x02192; Cu<sup>+</sup> + GSSG, Russell mechanism, <break/>
<sup>1</sup>O<sub>2</sub>-induced tumor inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-pharmaceutics-17-00244" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disulfide/thiol-induced GSH depletion <break/> Ce6@RMOF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i005.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i006.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GSH + RS-SR &#x02192; GSSG + RSH, <break/> PDT + Ferroptosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-pharmaceutics-17-00244" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azo-induced GSH depletion <break/> MOF@Ce6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i007.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i008.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azo &#x02192; GSH and thioredoxin <break/> depletion, PDT, <break/> 4T1 cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-pharmaceutics-17-00244" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> for GSH <break/> depletion <break/> CCP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i009.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i010.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> + GSG &#x02192; Cu<sup>+</sup> + GSSG, <break/> Heme oxygenase-1 activity suppression, CDT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-pharmaceutics-17-00244" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> for GSH <break/> depletion <break/> PCN-224(Cu)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i011.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i012.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> + GSG &#x02192; Cu<sup>+</sup> + GSSG, <break/> O<sub>2</sub> generation, FL + MRI, chemodynamic and starvation therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-pharmaceutics-17-00244" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> for GSH <break/> depletion <break/> O<sub>2</sub>-Cu/ZIF8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i013.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i014.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> + GSG &#x02192; Cu<sup>+</sup> + GSSG, <break/> Cu<sup>+</sup> + H<sub>2</sub>O<sub>2</sub> &#x02192; Cu<sup>2+</sup> + &#x000b7;OH, <break/> O<sub>2</sub> replenishment, PDT + CDT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-pharmaceutics-17-00244" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GSH adsorption to Zr<sup>4+</sup>
<break/> Zr-TCPP(Mn)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i015.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i016.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GSH depletion (adsorption to Zr<sup>4+</sup>), self-supply O<sub>2</sub>
<break/> Enhanced SDT + Ferroptosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-pharmaceutics-17-00244" ref-type="bibr">52</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: FL (fluorescence imaging); MRI (magnetic resonance imaging).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00244-t002"><object-id pub-id-type="pii">pharmaceutics-17-00244-t002_Table 2</object-id><label>Table 2</label><caption><p>Porphyrin-based nMOFs and their GSH depletion mechanisms for enhanced PDT applications.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Material</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Structure</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">GSH Depletion Mechanisms/Therapeutic Advantages</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Refs</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porphyrin</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoscale MOFs</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mn(III)-TCPP MOFs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i017.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i018.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mn<sup>3+</sup> + GSH &#x02192; GSSG + Mn<sup>2+</sup>, <break/> FL + MRI, <break/> 660 nm, 4T1 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-pharmaceutics-17-00244" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zr-TCPP <break/> MnFe2O4@MOF@PEG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i019.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i020.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mn<sup>4+</sup> + GSH &#x02192; GSSG + Mn<sup>2+</sup>, <break/> Fe<sup>3+</sup> + GSH &#x02192; GSSG + Fe<sup>2+</sup>, <break/> O<sub>2</sub> generation, 660 nm, 4T1 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-pharmaceutics-17-00244" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fe-TCPP nMOFs@HANPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i021.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i022.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fe<sup>3+</sup> + GSH &#x02192; GSSG + Fe<sup>2+</sup>, <break/> PDT + CDT, 635 nm, HA targeting, <break/> MR imaging, FL imaging, 4T1 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmaceutics-17-00244" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zr-TCPP <break/> Cu<sup>2+</sup>-MOF <break/> HN@Cu-MOF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i023.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i024.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> + GSH &#x02192; GSSG + Cu<sup>+</sup>, <break/> Cu<sup>+</sup> + H<sub>2</sub>O<sub>2</sub> &#x02192;&#x000b7;OH + Cu<sup>2+</sup>, <break/> Gas therapy (NO)+PDT, 4T1 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmaceutics-17-00244" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UCNPs <break/> PCN-224(Fe) <break/> UPFB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i025.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i026.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fe<sup>3+</sup> + GSH &#x02192; GSSG + Fe<sup>2+</sup>, <break/> Fe<sup>2+</sup> + H<sub>2</sub>O<sub>2</sub> &#x02192; OH + Fe<sup>3+</sup>, <break/> PDT + SDT + CDT, O<sub>2</sub> generation, US/808 nm activation, U14 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmaceutics-17-00244" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zr-TCPP <break/> MOF@Cu<sup>2+</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i027.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceutics-17-00244-i028.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu<sup>2+</sup> + GSH &#x02192; GSSG + Cu<sup>+</sup>, <break/> 638 nm, PDT, biofilm eradication/wound healing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-pharmaceutics-17-00244" ref-type="bibr">39</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>